Check for updates

OPEN ACCESS

EDITED BY Percy Schröttner, Technische Universität Dresden, Germany

REVIEWED BY Ruixue Zhang, Washington University in St. Louis, United States Wang Zhang, Sir Run Run Shaw Hospital, China Ignatius Ivan, Siloam Hospitals, Indonesia

*CORRESPONDENCE Ulrich Dobrindt Mobrindt@uni-muenster.de

RECEIVED 31 March 2025 ACCEPTED 07 May 2025 PUBLISHED 02 July 2025

CITATION

Keizers M, Mukherjee K, Berger M and Dobrindt U (2025) Less is more: the lack of autoinducer-2-dependent quorum sensing promotes competitive fitness of *Escherichia coli* strain 83972. *Front. Cell. Infect. Microbiol.* 15:1603759. doi: 10.3389/fcimb.2025.1603759

COPYRIGHT

© 2025 Keizers, Mukherjee, Berger and Dobrindt. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Less is more: the lack of autoinducer-2-dependent quorum sensing promotes competitive fitness of *Escherichia coli* strain 83972

Marla Keizers, Krishnendu Mukherjee, Michael Berger and Ulrich Dobrindt*

Institute of Hygiene, University of Münster, Münster, Germany

Autoinducer-2 is a signaling molecule involved in quorum sensing in Escherichia coli. Quorum sensing enables coordinated behavior based on cell density and helps bacteria adapt to their environment. The luxS gene and the lsr locus are involved in the biosynthesis, transport, and intracellular phosphorylation of autoinducer-2. Disruption of autoinducer-2 biosynthesis or transport can reduce biofilm formation, chemotaxis, and the expression of genes relevant for the uropathogenicity of E. coli. Interestingly, most isolates of E. coli phylogroup B2, in which uropathogenic and other extraintestinal pathogenic strains are overrepresented, lack the *lsr* operon. We show that autoinducer-2-dependent quorum sensing is not fundamentally beneficial for efficient and prolonged urinary bladder colonization. We demonstrate that the lsr-negative asymptomatic bacteriuria isolate 83972 has a higher fitness than its lsrcomplemented variant. Using transcriptome analyses, competitive growth assays, and comparisons of selected fitness properties, we show that restoration of the lsr operon in this strain background results in growth retardation, loss of competitiveness, and higher sensitivity to oxidative stress. Our results illustrate that the lack of autoinducer-2-dependent guorum sensing contributes to the well-known fitness and competitiveness of E. coli 83972, on which its effective use for bacterial interference in the urinary bladder relies. It is vital to delve deeper to fully understand the fitness and competitiveness of the ABU strain 83972 if we are to optimize its use in therapeutic colonization. The key is to unravel the underlying molecular mechanisms, thus ensuring the efficacy and safety of this treatment as an alternative to antibiotic therapy.

KEYWORDS

Isr locus, extraintestinal pathogenic E. coli, fitness, stress response, competitiveness

1 Introduction

Extraintestinal pathogenic Escherichia coli (E. coli) strains (ExPEC) are usually classified as facultative pathogens since they often colonize the gut without causing symptoms (Wiles et al., 2008; Köhler and Dobrindt, 2011). However, they harbor accessory traits that enable them to invade and colonize extraintestinal niches, eventually leading to symptomatic diseases (Vila et al., 2016; Sora et al., 2021). E. coli strains that have characteristic genetic markers that indicate the potential to cause extraintestinal disease, or that were directly isolated from infections outside the gastrointestinal system, are typically classified as ExPEC. ExPEC are usually divided into sepsis-causing (SEPEC), neonatal meningitis-associated (NMEC), and uropathogenic E. coli (UPEC), as well as strains causing systemic disease in animals such as avian pathogenic (APEC) or mammary pathogenic (MPEC) E. coli (Köhler and Dobrindt, 2011; Sora et al., 2021). Several virulence factors are described to promote extraintestinal pathogenicity in ExPEC, including adhesins, invasins, iron uptake systems, or toxins (Sora et al., 2021). Another bacterial trait that is involved in extraintestinal pathogenicity is quorum sensing (QS). Quorum sensing is a process in which bacteria sense and adapt to changing cell densities through signaling molecules called autoinducers (AI). Several AIs that are specific for certain bacterial strains or families have been described (Rutherford and Bassler, 2012). AI-2, on the other hand, serves as an interspecies signaling molecule that is produced and sensed by both Gram-positive and Gram-negative bacteria (Sun et al., 2004; Pereira et al., 2013). Even eukaryotic cells were proposed to participate in AI-2-mediated QS since it was found that Saccharomyces cerevisiae secretes molecules that mimic AI-2, as well as the intestinal epithelial cell (IEC) line Caco-2 in response to bacteria or a tightjunction disruption (Ismail et al., 2016; Valastyan et al., 2021). Moreover, the inflammatory interleukin IL-8 was found to be upregulated in response to external AI-2 in the IEC line HCT-8 (Zargar et al., 2015).

In bacteria, the precursor of AI-2, (S)-4,5-dihydroxy-2,3pentanedione (DPD) (Xavier and Bassler, 2005), is produced as a byproduct of L-homocysteine synthesis by the synthase LuxS, a widely distributed and conserved enzyme that is part of the activated methyl cycle (Schauder et al., 2001; Vendeville et al., 2005). DPD is a hydrophilic molecule that is actively transported out of the bacterial cell after production (Khera et al., 2022). Outside of the cell, DPD spontaneously circularizes into either boron-containing (S)-2methyl2,3,3,4-tetrahydroxytetrahydrofuran-borate or boron-free (R)-2-methyl-2,3,3,4-tetrahydroxytetrahydrofuran (R-THMF), resulting in two different types of active AI-2 (Chen et al., 2002; Miller et al., 2004). Depending on the environmental status, DPD can spontaneously convert between the two active forms and thus be sensed by mixed bacterial communities since both AI-2 forms are perceived by different receptors (Zhang et al., 2020). R-THMF, from now on referred to as AI-2, is an intracellular signaling molecule (Xavier and Bassler, 2005). Different receptors for AI-2 are known, but the best-studied is LsrB. LsrB was first described in Salmonella enterica serovar Typhimurium (S. Typhimurium) (Taga et al., 2001) and is part of a specialized transporter encoded in the lsr (LuxS-regulated) locus (Taga et al., 2003). The lsr locus, or homologs, have been found in various bacterial species, including *E. coli* (Pereira et al., 2009), and comprises two transcription units. The first transcription unit, *lsrRK*, encodes the kinase LsrK that phosphorylates the incorporated AI-2 and the repressor LsrR that represses transcription of both *lsr* operons (Xue et al., 2009), as well as of several other genes in *E. coli* (Li et al., 2007) and *S.* Typhimurium (Choi et al., 2012). The binding of phosphorylated AI-2 to LsrR abolishes the transcriptional repression, resulting in AI-2-dependent gene expression (Xavier and Bassler, 2005). The second transcription unit, *lsrACDBFG*, encodes structural proteins of the AI-2 transporter, i.e., LsrA, LsrC, LsrD, and LsrB as the receptor, as well as the isomerase LsrG that degrades the phosphorylated AI-2 and the thiolase LsrF that catalyzes the terminal step in processing phosphorylated AI-2 (Marques et al., 2014) (Figure 1).

Interfering with AI-2-dependent QS, either by using QS inhibitors (Helmy et al., 2022) or gene mutations and deletions, led to altered behavior and lower virulence in ExPEC strains. For example, the deletion of luxS has led to a significant reduction of virulence in the APEC O78:K80:H9 strain x7122 (Palaniyandi et al., 2013) and an attenuated virulence of the APEC strain DE17*DaroA* (Han et al., 2015). Also, the deletion of *lsrACD* in APEC94, which leads to an impaired AI-2 uptake and decreased bacterial motility, has led to lower bacterial loads and reduced virulence in a duckling infection model (Zuo et al., 2019). Additionally, it was shown that AI-2-dependent QS is associated with hydrogen peroxide (H₂O₂) resistance in the MPEC strain DCM5 (Wang et al., 2021) and antibiotic sensitivity in APEC strain APECX40 and the MPEC isolate DCM1 (Xue et al., 2016; Yu et al., 2020). Although AI-2-dependent QS has significant effects on APEC and MPEC, little is known about its effects on the virulence and fitness traits of UPEC, which are often genetically very similar to APEC and MPEC (Rodriguez-Siek et al., 2005; Tivendale et al., 2010). UPEC are the leading cause of urinary tract infections (UTI), one of the most prevalent bacterial infections worldwide, accounting for at least 75% of all complicated and uncomplicated cases (Flores-Mireles et al., 2015). Despite several host defense mechanisms, including the physicochemical composition of urine, the expression of antimicrobial peptides, or other innate immune response mechanisms (Abraham and Miao, 2015; Loubet et al., 2020), more than 50% of all women (Medina and Castillo-Pino, 2019) and about 20% of all men (Farrell et al., 2021) suffer at least from one symptomatic UTI episode during their lifetime. This indicates that UPEC strains are well adapted to the bladder environment and can combat the host's defense strategies (Flores-Mireles et al., 2015; Mann et al., 2017).

The asymptomatic bacteriuria (ABU) *E. coli* isolate 83972 evolved from UPEC but has lost the ability to express many functional virulence factors (Zdziarski et al., 2008). This strain is well adapted to long-term bladder colonization without causing inflammation or other UTI-related symptoms (Hull et al., 1999). Additionally, *E. coli* 83972 has a better antioxidant defense than UPEC strains (Aubron et al., 2012) and can outcompete UPEC strains in human urine, amongst others, probably due to fast growth and nutritional adaptation (Ipe et al., 2016; George et al., 2024). Due to these characteristics, deliberate bladder colonization by *E. coli* 83972 has been suggested as a therapeutic approach to prevent recurring UTI by bacterial interference (Sundén et al., 2010; Köves



et al., 2014; Wullt and Svanborg, 2016). Against the background of the increasing spread of multidrug-resistant bacteria, especially in the context of UTI, the use of antibiotics must be reduced (Cook and Wright, 2022). Bacterial interference by bladder colonization with ABU strain 83972 is an alternative way to prevent permanent colonization of the urinary bladder by symptomatic uropathogens (Wullt and Svanborg, 2016; Stork et al., 2018; Kenneally et al., 2022). Deeper insights into the importance of QS for the fitness and competitiveness of ABU strain 83972 may help to optimize the use of this bacterial strain for the deliberate therapeutic colonization of patients by uncovering underlying molecular mechanisms and thus improving the efficacy and safety of this form of treatment as an interesting alternative to antibiotic therapy. Interestingly, E. coli 83972 lacks the complete lsr locus but carries the luxS gene. We hypothesized that the absence of AI-2-dependent QS contributes to the strain's fitness during bladder colonization. Therefore, we integrated the full-length lsr locus from the E. coli K-12 strain MG1655 into the chromosome of E. coli 83972 and analyzed the transcriptome of the lsr complemented strain to screen for differentially expressed genes that are affected by AI-2-dependent QS and may be relevant during bladder colonization. Additionally, we tested for relevant bacterial phenotypes that may increase this strain's fitness in the urinary bladder.

2 Material and methods

Bacterial strains and culture conditions. The bacterial strains used in this study are listed in Supplementary Table S5. The asymptomatic bacteriuria *E. coli* isolate 83972 has been obtained as a gift from C. Svanborg (Lund, Sweden). Bacterial cultures were

either cultivated in lysogeny broth (LB) (10 g/L tryptone, 5 g/L yeast extract, and 5 g/L NaCl) or pooled human urine (four male and six female voluntary individuals, sterile filtered and mixed in a 1:1 male/female ratio (v/v)). When appropriate, antibiotics were added in the following concentrations: kanamycin (25 µg/mL), chloramphenicol (12.5 µg/mL), ampicillin (100 µg/mL), or zeocin (50 µg/mL). Bacterial strains were grown overnight at 37°C on LB agar plates (containing 1.5% agar (w/v)) with the appropriate antibiotics when needed. For overnight cultures, single colonies were picked and incubated in 2 mL of LB at 37°C and with orbital shaking at 180 rpm. E. coli DH5 was used as a host for plasmid construction. Genome manipulation was done by recombineering (Datsenko and Wanner, 2000). When indicated, cultures were supplemented with H₂O₂ (stabilized, Merck Millipore, Darmstadt, Germany) or synthetic DPD purchased from Rita Ventura's research group at ITQB-UNL (Oeiras, Portugal) (https:// itqb.unl.pt/research/chemistry/bioorganic-chemistry). Synthetic DPD was synthesized as published before (Ascenso et al., 2011), and the concentration was 16.8 mM. Both chemicals were subdiluted to working concentrations using sterile ddH₂O.

Cloning methods. DNA amplification for cloning and genetic manipulation was done using the Q5 High-Fidelity DNA Polymerase (New England Biolabs, Frankfurt/Main, Germany). Colony-PCR was done using the GoTaq Green Master Mix (Promega GmbH, Walldorf, Germany). After amplification, the correct size of amplicons was verified using agarose gel electrophoresis in 1x Tris-acetate-EDTA (TAE) buffer with 1-2% (w/v) agarose. The gels were run at 110–130 V for 30–60 min. Amplicons were purified using the NucleoSpin Gel and PCR Cleanup kit (Macherey-Nagel, Düren, Germany) or the Wizard SV Gel and PCR Clean-Up System kit (Promega, Walldorf, Germany). Plasmids were isolated using the NucleoSpin Plasmid Mini kit (Macherey-Nagel). Genomic DNA (gDNA) was isolated using the QIAamp DNA Mini kit (QIAGEN, Hilden, Germany). Purified PCR products were quantified using a spectrophotometer (NanoDrop 2000, Thermo Fisher Scientific, Schwerte, Germany). The restriction enzymes and T4 DNA ligase used for cloning were purchased from New England Biolabs (Frankfurt/Main, Germany).

Oligonucleotides and plasmids used. All oligonucleotides and plasmids used are listed in Supplementary Tables S6, S7.

Construction of pMK2. The plasmid pMK2 was constructed by integrating the *lsrA* promoter-*yfp* fusion reporter cassette coupled to *lsrR* (*lsrR*:P*lsrA*:*yfp* fusion) from the previously described *E. coli* K-12 strain MG1655 (*lsrA-G::yfp-cat*) (Keizers et al., 2022) into the low-copy number plasmid pWKS30 (Wang and Kushner, 1991). For that, the *lsrR*:P*lsrA:yfp* fusion was amplified from the gDNA of *E. coli* K-12 strain MG1655 (*lsrA-G::yfp-cat*) using the oligonucleotides pKD3_lsr_seq_4 and LZP50 and introduced into the *Sma*I-digested pWKS30 by using DNA T4 ligase. The correct insertion of the PCR product into pWKS30 was confirmed by plasmid preparation and subsequent Sanger sequencing.

Construction of pLS1 and pLS2. The low-copy-number plasmids pLS1 and pLS2 were constructed by integrating the *Pdps-cfp* (*cfp* under the control of the stationary phase-dependent *dps* promoter) cassette or the *Pdps-yfp* (*yfp* under the control of the stationary phase-dependent *dps* promoter) cassette, respectively, into pWKS30. Both cassettes were amplified using the oligonucleotides bla-TEM-r and MC_185 and pPS1 (*Pdps-cfp*) or pPS2 (*Pdps-yfp*) (Schiller et al., 2021) as templates. Amplicons and pWKS30 were cut with *Kpn*I and *SmaI*. All products were purified, and the digested *Pdps-cfp* cassette was introduced into digested pWKS30, resulting in pLS1. The digested *Pdps-yfp* cassette was introduced into digested pWKS30, resulting in pLS2. Ligation was done using DNA T4 ligase. Correct plasmids were confirmed by fluorescence microscopy.

Construction of *E. coli* strains 83972 $\Delta luxS$ and 83972 $\Delta ybhC$. For the construction of *E. coli* 83972 $\Delta luxS$, the *luxS* gene was replaced by a zeocin resistance cassette (*bleR*) that was amplified using the oligonucleotides Rec_BleoR_fwd and Rec_BleoR_rev and pEM7/Zeo as a template. Replacement was confirmed by colony PCR using the oligonucleotides CFT073_ Δ luxS_CP_fwd and CFT073_ Δ luxS_CP_rev and Sanger sequencing of the purified amplicon. For the construction of *E. coli* strain 83972 $\Delta ybhC$, the *ybhC* gene was replaced by a chloramphenicol resistance cassette (*cat*) that was amplified using the oligonucleotides del_ybhC_fwd and del_ybhC_rev and pLP2 (Peng et al., 2022) as a template. Replacement was confirmed by colony PCR using the oligonucleotides wt_PybhC and LZP18 and Sanger sequencing of the purified amplicon.

Construction of *E. coli* strains 83972 *attB::lsr* and 83972 $\Delta luxS$ *attB:: lsr*. First, the plasmid pWKS30_LSR was generated. The chloramphenicol resistance cassette (*cat*) was introduced upstream of the *lsr* locus in the chromosome of *E. coli* strain MG1655 by recombineering (Datsenko and Wanner, 2000). The resistance cassette was amplified using the oligonucleotides CBL_fwd and CBL_rev and pMB54 (Berger et al., 2016) as a

template. The correct chromosomal insertion was confirmed by colony PCR using the oligonucleotides LKRS_fwd and pMB54_lsrRK_CP1_rev. In the same way, the kanamycin resistance cassette (aph) was chromosomally inserted downstream of the lsr locus in the resulting E. coli strain MG1655 cat_lsr. The aph resistance cassette was amplified using the oligonucleotides RBL_fwd and RBL_rev and pKD4 as a template. The correct chromosomal insertion was confirmed by colony PCR using the oligonucleotides pKD3_lsr_seq_12 and LZP50. The full-length lsr locus, flanked by cat and aph, was amplified from gDNA of the resulting E. coli strain MG1655 cat_lsr_aph using the oligonucleotides LKRS_fwd and LZP50, and cloned into the SmaI-digested pWKS30 by using DNA T4 ligase. The relevant parts of the resulting plasmid pWKS30_LSR were afterward confirmed by Sanger sequencing. The complete lsr determinant was then inserted by recombineering (Datsenko and Wanner, 2000) next to the chromosomal attachment site of the bacteriophage λ (attB) in either E. coli 83972 or strain 83972 AluxS. For this, the lsr locus flanked by cat and aph (cat_lsr_aph) was amplified using the oligonucleotides pWKS30_attB_fwd and pWKS30_attB_rev and pWKS30_LSR as a template and introduced next to the λ attB site of the strains 83972 and 83972 $\Delta luxS$, respectively. The correct chromosomal insertion was confirmed by colony PCR using the oligonucleotides CFT073_lsrRK_YFP_CP1_fwd and pKD3_lsr_seq_12 or CFT073_lsrRK_YFP_CP1_fwd and CFT073_lsrRK_YFP_CP2_rev and pKD3_lsr_seq_13. Afterward, gDNA was isolated, and the cat_lsr_aph region was amplified using the primer pair CFT073_lsrRK_YFP_CP1_fwd and CFT073_lsrRK_YFP_CP2_rev before the correctness of the DNA sequence was also verified by Sanger amplicon sequencing.

RNA isolation. Total RNA was isolated as previously described (Wallenstein et al., 2020) with the following differences: Overnight cultures of *E. coli* strains 83972 and 83972 *attB*::*lsr* were diluted to a final optical density OD600 = 0.02 in 200 mL LB. At indicated time points, 70 mL of culture (lag phase), 5 mL of culture (exponential phase), or 2 mL of culture (stationary phase) were added to the 0.2x volume of pre-chilled stop solution, and the bacterial pellets were directly lysed. Confirmation of complete gDNA removal was done by qPCR. RNA was extracted from three biological replicates for each strain.

RNAseq and data analysis. Strand-specific cDNA libraries were prepared from the isolated RNA and sequenced (Illumina NextSeq 500, 1 x 75 bp single reads) by vertis Biotechnology AG (Freising, Germany). The obtained raw reads were analyzed as follows: Quality control using FastQC and MultiQC (Bioinformatics; Ewels et al., 2016), adaptor trimming using Cutadapt (Martin, 2011) with subsequent quality control, alignment of reads using burrows-wheeler alignment (Li and Durbin, 2009) to the genome of *E. coli* 83972 *attB::lsr* with a subsequent strandedness check using RSeQC (Wang et al., 2012) and quality control, count reading using featureCounts (Liao et al., 2014) and a subsequent differentially expressed gene analysis using DESeq2 (Love et al., 2014) in R. Conversion of formats was done using AGAT (Dainat, 2022). The subsequent data analysis was done in R. The Venn diagram (Figure 2A) was made using venn.diagram (Chen, 2022). The heatmaps (Figures 2B–D) were made using pheatmap (Kolde, 2019). Differentially expressed genes were clustered using dist() and hclust(), and biological replicates were clustered using pheatmap (cluster_cols = T) with the complete linkage method for hierarchial clustering. The scatterplots (Supplementary Figure S2) were computed using pairs.panels() from the package psych (Revelle, 2023).

Growth analysis and co-culture assays. For growth analysis, overnight cultures of the bacterial strains were diluted to a final optical density (OD600) of 0.01 in 1 mL of fresh medium with antibiotics when appropriate. 200 µL of freshly diluted cultures were added into one well of a 96-well plate (Thermo Fisher Scientific, Schwerte, Germany) in duplicates for each biological replicate. For the subsequent growth analysis, either an Infinite M NANO+ or an Infinite F200 microplate reader (both from TECAN, Männedorf, Switzerland) was used. The optical density was either measured at 595 nm (± 9 nm) (M NANO+) or 595 nm (± 10 nm) (F200). Signals were measured in ten-minute intervals. The resulting growth curves were analyzed using AMiGA (Analysis of Microbial Growth Assay (Midani et al., 2021)). For the lag phase length analysis, the data was not log-transformed. The co-culture assays were performed as previously described (Keizers et al., 2022). Briefly, overnight cultures of the strains to be analyzed were mixed in a 1:1 ratio with the E. coli K-12 reporter strain MG1655 ΔluxS attB::PlsrA-yfp to a final optical density (OD600) of 0.02. Growth analysis was performed as described above, and the fluorescence signal was either measured using an excitation wavelength of 514 nm (± 9 nm) and an emission wavelength of 550 nm (± 20 nm) (M NANO +) or using an excitation wavelength of 485 nm (\pm 20 nm) and an emission wavelength of 535 nm (± 25 nm) (F200).

Competition assays. For the competition assays, overnight cultures of E. coli strains 83972 (pLS2) and 83972 attB::lsr (pLS1) were mixed in a 1:1 ratio to a final optical density (OD600) of 0.02 in 25 mL of fresh medium supplemented with ampicillin. The cultures were grown at 37°C with orbital shaking at 180 rpm. After 3 h of growth, the cultures were subdiluted into 25 mL of fresh medium containing ampicillin with an appropriate dilution factor (1:200 for LB and 1:10 for pooled human urine). After subdilution, the cultures were grown for another 3 h. The subdilution procedure was repeated three times with a total assay time of 12 h. For the long-term competition, the cultures were grown at 37°C with orbital shaking at 180 rpm for 72 h. Directly after mixing and at the indicated time points, aliquots were taken from the cultures and microscopically analyzed using a Leica inverted microscope DMi8 with an attached camera at 400 x magnification. For each aliquot, ten microscopic pictures were taken with three channels each -Differential interference contrast (DIC), cyan fluorescent protein CFP (excitation 436 nm (± 20 nm); dichroic mirror 455 nm; emission 480 nm (± 40 nm) and fluorescein isothiocyanate (FITC) (excitation 480 nm (± 40 nm); dichroic mirror 505 nm; emission 527 nm (± 30 nm). Next, the number of bacteria per picture was quantified in the CFP channel and the FITC channel using an ImageJ script. The ratio of bacterial numbers in the FITC channel compared to the total bacterial numbers in both the FITC and CFP channels was calculated for each of the ten pictures, resulting in one mean ratio value with a standard deviation for each time point and biological replicate.

 $\rm H_2O_2$ resistance assay. For the $\rm H_2O_2$ resistance assay, overnight cultures of the bacterial strains were diluted to a final optical density (OD600) of 0.01 in 1 mL of fresh medium. 190 µL of freshly diluted cultures were added into one well of a 96-well plate (Thermo Fisher Scientific) in duplicates for each biological replicate. After adding cultures, 10 µL of H₂O₂ diluted in ddH₂O was added into each well, resulting in the indicated final H₂O₂ concentrations. The growth was analyzed directly after the addition using an Infinite M NANO+ plate reader (TECAN) or an Infinite F200 (TECAN). The optical density was either measured at 595 nm (\pm 9 nm) (M NANO+) or 595 nm (\pm 10 nm) (F200). Signals were measured in ten-minute intervals. The resulting growth curves were analyzed using AMiGA (Analysis of Microbial Growth Assay (Midani et al., 2021)). For the lag phase length analysis, the data was not log-transformed.

Galleria mellonella larvae feeding assay. Galleria mellonella larvae were purchased from Fauna Topics Zoobedarf Zucht und Handels GmbH (Marbach am Neckar, Germany) and reared on an artificial diet (22% maize meal, 22% wheat germ, 11% dry yeast, 17.5% beeswax, 11% honey, and 11% glycerin) as previously described (Mukherjee et al., 2020). To evaluate the fitness of the E. coli wild type strain 83972 and its lsr-complemented mutant in the larval digestive tract, overnight cultures (OD 600 = 1, grown in LB) of both strains were mixed in a 1:1 ratio and force-fed to sixthinstar larvae (weighing approximately 250-300 mg) (Lange et al., 2019). A 10-µL aliquot of this bacterial suspension was gently introduced into the larval mouth using 1-mL disposable syringes fitted with 0.4 x 20-mm needles mounted on a microapplicator. Control larvae received an equivalent volume (10 µL) of sterile LB. Following force-feeding, larvae were incubated at 37°C for 24 hours without food. All larvae survived the incubation period and were subsequently flash-frozen in liquid nitrogen, ground into a fine powder, and homogenized in LB. The homogenates were then plated onto LB agar, and colony-forming units (CFUs) were counted following a 24-hour incubation at 37°C. The survival of the wild type and lsr-complemented mutant strains was analyzed by comparing their initial inoculation ratio to the ratio recovered from larvae after 24 hours of incubation.

Detection of the *lsr* determinant in *E. coli* genomes. To screen for the presence and conservation of the *lsr* determinant in *E. coli*, all published *E. coli* genomes that were available at the time point of the analysis were downloaded from NCBI Assembly (Kitts et al., 2016) (time point of download: 15.03.2023) in FASTA format (Status: latest RefSeq). In total, 32,594 genomes were downloaded. Next, the phylogroup was determined using ClermonTyping (Beghain et al., 2018) for each genome. The analysis was continued with 32,404 genomes belonging to the phylogroups A, B1, B2, C, D, E, F, and G. Next, each genome was analyzed using the basic local alignment search tool (BLAST+ (Camacho et al., 2009)) to screen for the nucleotide sequence (blastn) of the full-length *lsr*



FIGURE 2

Complementation of *E. coli* 83972 with the *lsr* determinant and its impact on AI-2 synthesis, uptake and LsrK phosphorylation. The full-length *lsr* locus was introduced into *E. coli* 83972, and subsequent analyses revealed *luxS*-dependent AI-2 synthesis, the functionality of the complemented gene *lsrK* and the functionality of AI-2 uptake. **(A)** The *lsr* determinant flanked by two resistance cassettes (12,520 bp) was integrated into the chromosomal *attB* site of *E. coli* 83972. The *luxS*-dependent AI-2 synthesis was analyzed by fluorescence kinetics (100–800 min), depicted as RFU, during co-culture with the reporter strain *E. coli AluxS* (*attB::PlsrA-yfp*) (Keizers et al., 2022). Co-cultures consisting of the reporter strain and **(B)** either *E. coli* 83972 (grey squares) or *E. coli* 83972 *AluxS* (white squares) or **(C)** *E. coli* 83972 *attB::lsr* (grey squares) and *E. coli* 83972 *AluxS* attB:: lsr (white squares) in a 1:1 ratio in LB. Error bars represent the results of three biological replicates in duplicates each. **(D)** The functionality of the complemented gene *lsrK* was analyzed by incorporating the reporter plasmid pMK2 (comprises *lsrR* and the *PlsrA-yfp* reporter module) into *E. coli* strains 83972 *AluxS* att8::*lsr* (pMK2) after the addition of 25 µM DPD compared to water during the late-exponential growth phase, as described before (Keizers et al., 2022). Statistical analysis was performed using the ordinary two-way ANOVA with Tukey's multiple compared to water during the late-exponential growth phase, as described before (Keizers et al., 2022). Statistical analysis was performed using the ordinary two-way ANOVA with Tukey's multiple compared to water during the late-exponential growth phase, as considered statistically significant. Error bars represent the results of five biological replicates in duplicates each. **(F)** Relative AUC calculation of *PlsrA* induction in *E. coli* strains 83972 *AluxS* (pMK1) and 83972 *AluxS* attB::*lsr* (PMK1) and 83972 *AluxS* attB::*lsr* (PMK1

locus (*lsrRK-lsrACDBFG*), the *luxS* gene and the *tam* gene (reference sequences from the *E. coli* K-12 strain MG1655). Output possibilities were "complete" (blastn hit length equal query length), "incomplete" (blastn hit length inequal query length), "no match" (no blastn hit) or "multiple matches" (multiple blastn hits). The output "< 100 bp" is a summary of a

blastn hit length of below 100 bp and the "no match" hits. Please note that our analysis only focuses on gene length, whereas the functionality of the encoded gene product was not part of the analysis.

Statistical analysis. Statistical analysis was performed using GraphPad Prism v8.0.2 (San Diego, USA).

3 Results

3.1 Complementation of *E. coli* 83972 with the *lsr* locus: impact on AI-2 uptake, synthesis and secretion

We complemented E. coli strain 83972 with the lsr locus by integrating the full-length lsr determinant (lsrACDBFG and lsrRK operons), flanked by two resistance markers, into the chromosomal attachment site (*attB*) of the bacteriophage λ (Figure 2A). The resulting E. coli strain 83972 attB::lsr, the wild type strain 83972, as well as their isogenic luxS deletion mutants (83972 \DuxS and 83972 \DuxS attB::lsr), were used for further analysis. The ability of strains 83972 and 83972 attB::lsr to secrete AI-2 was evaluated in co-cultures with the reporter strain E. coli AluxS (attB::PlsrA-yfp), as described previously (Keizers et al., 2022). We detected AI-2-dependent YFP-expression in the cocultures with E. coli 83972 and E. coli 83972 attB::lsr, whereas we observed no YFP-expression in co-cultures with the isogenic luxS deletion strains. Both strains 83972 and 83972 attB::lsr synthesized AI-2in a *luxS*-dependent manner and exported it, which can be sensed by the PlsrA reporter strain in the co-culture. In the presence of the lsr determinant, E. coli 83972 can accumulate additional AI-2, leading to a stronger lsrA promoter induction in the reporter strain (Figures 2B, C).

To test if the lsr-complemented strain was capable of taking up and phosphorylating AI-2, we introduced pMK2, a derivative of the previously described reporter plasmid pMK1 that lacks lsrK (Keizers et al., 2022), into the strains 83972 ∆luxS and 83972 $\Delta luxS$ attB::lsr (Figure 2D). The functionality of LsrK was analyzed by supplementing the growth medium with 25 µM synthetic DPD in the late logarithmic growth phase and comparing the AI-2-dependent YFP expression to a water control. There was no significant difference in YFP expression between E. coli 83972 AluxS (pMK2) supplemented with 25 µM DPD and the water control. The expression of the AI-2 kinase LsrK in E. coli 83972 AluxS attB::lsr (pMK1) led to a significantly higher YFP expression when the strain was supplemented with 25 μ M DPD as compared to the water control (p < 0.001) (Figure 2E). To determine if the observed differences were due to an overall defect in AI-2 uptake in the lsr-negative 83972 wild type strain, we introduced the reporter plasmid pMK1 into E. coli 83972 AluxS and E. coli 83972 *AluxS attB::lsr*. Again, AI-2 uptake was analyzed by supplementing the medium with 10 μ M synthetic DPD in the late logarithmic growth phase and comparing the AI-2-dependent YFP expression to a water control. In both strains harboring pMK1, we detected a significantly higher YFP expression after the addition of 10 μ M DPD relative to the corresponding water controls (p < 0.001). This confirmed that external AI-2 can be taken up by E. coli 83972 in an LsrACBD-independent way (Figure 2F).

3.2 Influence of the *lsr* determinant on global gene expression in *E. coli* 83972

To analyze the effect of AI-2-dependent quorum sensing on the transcriptome, we performed an RNA-seq analysis of *E. coli* strains

83972 and 83972 attB::lsr. Both strains were cultivated in LB, and samples were taken in the lag phase, during mid-exponential growth (exp. phase), and during the transition to the stationary phase (stat. phase) (Supplementary Figure S1). We isolated total RNA from three biological replicates of each strain and time point for RNAseq analysis. For each library, we obtained ~ 11.5×10^6 reads (\pm 2 x 10⁶ reads), from which, on average, ~ 89% (\pm 3-5%) were mapped to the reference genome (E. coli 83972 attB::lsr). Data analysis was done using DESeq2 in R (Love et al., 2014), and the resulting expression data was used for further analysis (Supplementary Figure S2). The transcriptome analysis revealed 492 significantly differentially expressed genes (DEG; adjusted pvalue < 0.05) in E. coli 83972 attB::lsr compared to the wild type strain 83972 in the three growth phases. A complete list of all DEGs is provided in the Supplementary Table S1. Of the 492 DEGs, 199 genes had a log2-fold change (L2FC) in expression of at least 1 (DEG (± 1 L2FC)). Among all DEG (± 1 L2FC), nine genes were differentially expressed during all three growth phases (Figure 3A). We found 60 DEG (\pm 1 L2FC) in the lag phase, 67 DEG (\pm 1 L2FC) during mid-exponential growth, and 72 DEG (± 1 L2FC) during the transition to the stationary phase (Figures 3B-D). Besides lsrR, lsrK and the two resistance cassettes aph and cat that were used to complement E. coli 83972 attB::lsr, genes related to the isoleucine/ valine biosynthesis pathway, namely *ilvNBAG*, were upregulated, and the gene ybhC, which encodes an uncharacterized protein that was suggested to be involved in H₂O₂ resistance, was downregulated in all three growth phases. The DEG (± 1 L2FC) can be functionally clustered into four main groups, i.e., metabolism, motility/biofilm formation/adhesion, growth and stress response, and some remaining genes (Tables 1-5).

In the lag phase, mainly biosynthesis genes were upregulated. Together with the genes of the valine, leucine, and isoleucine biosynthesis pathway (ilvNBAMDEGC), also genes of the nrd operon, encoding for a ribonucleotide reductase (nrdHIEF) were significantly upregulated. On the contrary, several metabolic genes were downregulated. We found that genes involved in arginine uptake and metabolism (argT), sulfur utilization (ssuD), or coding for an alanine/glycine:cation symporter (yaaJ), as well as a mannonate dehydratase (rspA) were downregulated. Also, the expression of genes associated with the aminoacyl-tRNA biosynthesis of lysine (trnK1-5) and valine (trnV3-5) or with resistance against extracytoplasmic stress (cpxP) was downregulated. Amongst all genes that were downregulated in strain 83972 in the presence of the lsr determinant in the lag phase, more than 50% code for components of the flagellar assembly apparatus. In addition to the flagellar sigma factor $\sigma 28$ encoding gene *fliA*, the transcriptional regulator gene *fliZ*, and the chaperone gene flgN, nearly all flagellar genes belonging to class 2 were downregulated (fliE, fliFG, fliI, fliLMNOP, flhBA, flgBCDE, flgGHI, and flgA).

During mid-exponential growth, we predominantly found genes associated with metabolic pathways upregulated in *E. coli* 83972 *attB*::*lsr* relative to *E. coli* strain 83972. The encoded gene products are involved in the metabolism of D-serine (*dsdA*), glutamate (*gltI*), glycine (*gcvPH*), L-lactate (*lldD*), sorbitol (*srlD*),



L-alanine (dadX, ygaW), glycerol (glpDTQK), proline (putAP), Nacetylneuraminate (nanMKE-yhcH), dihydroxyacetone (dhaM) as well as the TCA cycle (sucBCD). Also, three genes encoding outer membrane proteins (ompF and the outer membrane porin protein LC precursor) were upregulated. The genes coding for the valine, leucine, and isoleucine biosynthesis pathway (ilvNBADEGC) were upregulated. Interestingly, we also found upregulated genes involved in stress response, including the nitrogen starvation gene *ycjX*, the heat-shock protein gene *ibpB*, and the pH-stress response protein gene inaA. On the contrary, the gene cluster aceEF, encoding a pyruvate dehydrogenase, was downregulated during mid-exponential growth. Of all downregulated genes during midexponential growth, 36% are associated with iron sensing and utilization, including the genes coding for the ferric siderophore reductase (fhuF), the ferric chelate reductase (yqjH), the ferric citrate transporter genes (fecA) and (fecD), the ferrous iron permease and transport genes efeU, ycdB, and ycdO, the energy transducing Ton complex subunit gene exbB and pmrR, which is associated with the iron and acidic pH sensing BasSR complex. Additionally, apart from *ybhC*, the superoxide dismutase SodAencoding gene was downregulated. The latter two proteins have been described to protect against oxidative stress.

As expected, we observed that the genes of the lsr locus were highly expressed during the transition to the stationary phase. Also, the expression of valine, leucine, and isoleucine biosynthesis pathway genes (ilvGABN) and genes contributing to magnesium sensing and utilization were upregulated. These included the import-associated genes mgtA and mgtS and the Mg2+-induced kinase gene yrbL. Interestingly, several genes associated with general stress response were upregulated. These included marB, encoding the protein MarB that reduces the transcription rate of marA, which codes for a pleiotropic regulator also involved in general stress response. The expression of *ycfR*, which is involved in stress response and outer membrane permeability was also upregulated. We also detected that the transcript levels of several genes (focDFGHYX) of the F1C fimbrial operon were significantly increased in E. coli 83972 attB::lsr in comparison to E. coli strain 83972. The main proportion of downregulated genes, was related to

Gene name	log2- fold change	Pathway/function ^{82–84}		
lag phase	lag phase			
ybhC	-3.442713222	pentose and glucuronate interconversions		
ssuD	-1.736408299	sulfur metabolism		
argT	-1.686346996	lysine/arginine/ornithine ABC transporter		
yaaJ	-1.090400775	alanine or glycine:cation symporter		
rspA	-1.020974991	pentose and glucuronate interconversions		
putA	1.245756938	alanine, aspartate and glutamate metabolism; arginine and proline metabolism		
ilvN	1.272441162	butanoate metabolism; C5-Branched dibasic acid metabolism/valine, leucine and isoleucine biosynthesis; pantothenate and CoA biosynthesis		
nadA	1.292375467	nicotinate and nicotinamide metabolism		
ilvB	1.403448526	butanoate metabolism; C5-Branched dibasic acid metabolism; valine, leucine and isoleucine biosynthesis; pantothenate and CoA biosynthesis		
ilvA	2.26260477	glycine, serine and threonine metabolism; valine, leucine and isoleucine biosynthesis		
ilvM	2.345314152	butanoate metabolism; C5-Branched dibasic acid metabolism; valine, leucine and isoleucine biosynthesis; pantothenate and CoA biosynthesis		
ilvD	2.459224415	valine, leucine and isoleucine biosynthesis; pantothenate and CoA biosynthesis		
ilvE	2.660495823	cysteine and methionine metabolism; valine, leucine and isoleucine degradation; valine, leucine and isoleucine biosynthesis; pantothenate and CoA biosynthesis		
ilvG	3.063866229	butanoate metabolism; C5-Branched dibasic acid metabolism; valine, leucine and isoleucine biosynthesis; pantothenate and CoA biosynthesis		
ilvC	4.371339203	valine, leucine and isoleucine biosynthesis; pantothenate and CoA biosynthesis		
exp. phase	exp. phase			
ybhC	-3.005651583	pentose and glucuronate interconversions		
fhuF	-2.013029339	ferric iron reductase		
fecD	-1.925348313	iron-dicitrate ABC transporter subunit		
aceE	-1.523183226	glycolysis; gluconeogenesis; citrate cycle (TCA cycle); pyruvate metabolism; lipoic acid metabolism		
ycdB	-1.472910514	iron uptake system component		
aceF	-1.398523034	glycolysis; gluconeogenesis; citrate cycle (TCA cycle); pyruvate metabolism; lipoic acid metabolism		
ycdO	-1.354592654	iron uptake system component		
удјН	-1.302729542	ferric-chelate reductase		
efeU	-1.289042204	ferrous iron permease		
fecA	-1.188669015	ferric citrate outer membrane transporter		
exbB	-1.172171856	enterochelin uptake protein		
sucB	1.003798232	citrate cycle (TCA cycle); lysine degradation; tryptophan metabolism; lipoic acid metabolism		
dhaM	1.010654719	glycerolipid metabolism		
gcvP	1.084269904	glyoxylate and dicarboxylate metabolism; glycine, serine and threonine metabolism; lipoic acid metabolism		
ilvC	1.225445888	valine, leucine and isoleucine biosynthesis; pantothenate and CoA biosynthesis		
glpK	1.237027056	glycerolipid metabolism		
ROK family protein	1.2491515	amino sugar and nucleotide sugar metabolism		

TABLE 1 Differentially expressed genes in E. coli 83972 attB::lsr relative to E. coli 83972 associated with metabolism.

(Continued)

TABLE 1 Continued

eye eve eve eve eve eve eve eve eve eve	Gene name	log2- fold change	Pathway/function ^{82–84}	
intervalinterval $inter cycle(intercycle): propuose metabolism; CS-Branched albasic acid metabolismpaiP132892333iodianipolitic symporterglut133854322glutanato iaparitate transport systemnadA1341088incinitate and nicerinamide metabolismglut133854632glycerlo-3/polyalate transporterglut1348746661glycerlo-3/polyalate transporterglut1438108507I-Alainer exporterglut1438108507I-Alainer exporterglut1438108508glycern-3/polyalpid metabolismglut1438108508glycern-s/polyalpid metabolismglut1438108508glycernyboopholipid metabolismglut143978580glycernyboopholipid metabolismglut143978763glycernyboopholipid metabolismglut143978763glycernyboopholipid metabolismglut143978763glycernyboopholipid metabolismglut143978763glycernyboopholipid metabolismglut143978763glycernyboopholipid metabolismglut143978763glycernyboopholipid metabolismglut143978763glycernyboopholipid metabolismglut143978763glycernyboopholipid metabolismglut154974763glycernyboopholipid metabolismglut1438178763glycernyboopholipid metabolismglut1438178763glycernyboopholipid metabolismglut154978763glycernyboopholipid metabolismglut1549$	exp. phase			
prior1.32692353iodium/yoine sympetregkl1.30564322gkitmata/saparate transport systemmkl1.30564323gkitmata/saparate transport systemmkl1.3641093iodium/yoine sympetregkl1.56746661gyccrophosphalte transportmkl1.56746661gyccrophosphalte transportgkl1.40364876gyccrophosphalte transportgkl1.40364876gyccrophosphaltel matabilamgkl1.40364876gyccrophosphaltel matabilamgkl1.40364876gyccrophosphaltel matabilamgkl1.40374409gyccrophosphaltel matabilamgkl1.40374409gyccrophosphaltel matabilamgkl1.5978413gyccrophosphaltel matabilamgkl1.5978413gyccrophosphaltel matabilamgkl1.7873703gitche series and thronine metabolism; glycine, series and thronine metabolism; lipic acid metabolismgkl1.81291740Gycine, series and thronine metabolism; glycine, series and thronine metabolismgkl1.81291741Boxine and nacione incibolismgkl1.81291745Guctore and manore metabolismgkl1.81291745Guctore and machine incibolismgkl1.81291745Initios gar and naciotike isgar metabolism; valine, leacine and isoleacine biosynthesisgkl2.8056469mino sagar and naciotike isgar metabolism; valine, leacine and isoleacine biosynthesis pantohemate andgkl2.8676205Sigcrite and metabolism; valine, leacine and isoleacine biosynthesis pantohemate andgkl3.83237636Naccin	dsdA	1.265931194	glycine, serine and threonine metabolism; D-Amino acid metabolism	
glin133054322glittamate/unsport systemnadA136410938nicotinant and nicotinantide metabolismgliT1.56746661glycerol-3-phosphate transportersucD1.582561251etrate cycle (TCA sycle) programate metabolism, C5-Branched dibasic acid metabolismgliQ1.50146661glycerol-boxpholipil metabolismgliQ1.501567glycerophospholipil metabolismgliQ1.400831967k-Ascriptocuranitate opinerasegriQ1.5074130glycerophospholipil metabolismnaMM1.99541909N-accriptocuranitate opinerasegriH1.5074130glycerophospholipil metabolism glycine, serine and threenine metabolism: lipoic acid metabolismniDA1.79737930valine, lexicine and iodexilne blosynthesis pantothemate and CoA blosynthesisibiA1.57847262glycene, serine and threenine metabolism: gycline, serine and threenine metabolism: lipoic acid metabolismibiA1.28132762glycene serine and threenine metabolism: yaline, lexicine and iodexine blosynthesisadatX1.81211714D-Arrino acid metabolismatabite1.83790231dainine, aspart and alcoholish agar metabolism: yaline, lexicine and iodexine blosynthesisnarK2.9395031ataine, aspart and naclootike sagar metabolism; valine, lexiche and iodexine blosynthesisnarK2.9395032sportser and metabolism; C3-Branched dibasic acid metabolism; valine, lexiche and iodexine blosynthesis; pantothemate and CA blosynthesisnarK2.94747575bactroser metabolism; C3-Branched dibasic acid metabolism; valine, lexiche and iodexine blosynthesis; pantothemate and	sucC	1.271455252	citrate cycle (TCA cycle); propanoate metabolism; C5-Branched dibasic acid metabolism	
nakal13641093knotinitar and nicotinamide metabolismgb7136766661givecrol-3-phosphate transporternacD1382561231citrae cycle (TCA cycle); propanote metabolism, CS-Branched dibasic acid metabolismgbq01382561231citrae cycle (TCA cycle); propanote metabolism, CS-Branched dibasic acid metabolismgbq0143616867givecrophospholipid metabolismgbq1143616876givecrophospholipid metabolismgbq114361687givecrophospholipid metabolismgbq115951690N-excytinecruminate cpimerasegcr41597413givecrophospholipid metabolism: glycine, serine and threonine metabolism; lycine, serine and threonine metabolism; lycine, serine and threonine metabolism; upine, leucine and isolencine biosynthesisibiA15787303value, leucine and isolencine biosynthesis partothemate and CoA biosynthesisibiA158211917D-Anino acid metabolism; upine, leucine and isolencine biosynthesisibiA181211917D-Anino acid metabolism; urginine and proline metabolismibiA182970673fructore and manore metabolism; urginine and proline metabolismibiA20396088aninos sagar and nucleotide sugar metabolismibiA20396080aninos sagar and nucleotide sugar metabolism; urgine, leucine and isolencine biosynthesis; pantothemate andibiA204961730gistanoate metabolism; CS-Branched dibasic acid metabolism; value, leucine and isolencine biosynthesis; pantothemate andibiA204962731batanoate metabolism; CS-Branched dibasic acid metabolism; value, leucine and isolencine biosynthesis; pantothemate and <t< td=""><td>putP</td><td>1.326926235</td><td>sodium/proline symporter</td></t<>	putP	1.326926235	sodium/proline symporter	
hereIsoreactiongeneral-spherophare transportersuch138250210ctrate cycle (TCA cycle); propanate metabolism; CS-Branched dibasis acid metabolismyglv140813040LAlanine exporterglvD140548576giccrophospholipid metabolismglvD140548570giccrophospholipid metabolismglvD147953806giccrophospholipid metabolismglvD147954800giccrophospholipid metabolism; glytics serial and theronine metabolism; lipito acid metabolismglvD147954700giccrophospholipid metabolism; glytics serial and theronine metabolism; lipito acid metabolismglvD147954700giccrophospholipid metabolism; glytics serial and licolocythesisafvAC181927620chronic and allocharche biosynthesis partochente and CoA biosynthesisafvAC181927680chronic and andonocure biosynthesis partochente and Solocitic biosynthesisafvAC181927680chronic and aduation serial biosin; arginine and pioline metabolismafvAC18935688quines quart and allumate metabolism; arginine and proline metabolismafvAC18935688quines quart and aduation segar metabolism; arginine and proline metabolismafvAC18935688quines quart and aduation segar metabolism; arginine and proline metabolism; arginine and proline metabolism; allunci, leacine and isoleacine biosynthesisafvAC18935688quines quart and aduation segar metabolism; allunci, leacine and isoleacine display displ	gltI	1.330564322	glutamate/aspartate transport system	
numberinstruct order (TCA cycle); roppunate metabolism; C5-Branched dibasic acid metabolismggW140831967i-Alanine exporterggPQ1435148876glycorophospholipid metabolismghPQ1477788006glycorophospholipid metabolismghPQ1479788007glycorophospholipid metabolismghPQ1479788007glycorophospholipid metabolismghPQ1479788007glycorophospholipid metabolismghPQ15878413glycorophospholipid metabolism glycine, serine and theoraine metabolism; lipicia caid metabolismghPQ15878413glycine, serine and theoraine metabolism; spatiathenate and GoA biosynthesisdhAT158194762glycine, serine and theoraine metabolism; arginine and isoleacine biosynthesisdhAT181297687fractose and manose metabolism; arginine and proline metabolismmRA189396083amino sugar and nucleotide sugar metabolism; arginine and proline metabolismmRA203956083amino sugar and nucleotide sugar metabolism; arginine and proline metabolismmRA204864504grywate metabolism; cylinice and insoleacine displacticne biosynthesismRA204864503grywate metabolism; valine, leuxine and isoleacine biosynthesisibRA204864504sanator metabolism; valine, leuxine and isoleacine biosynthesis; pantothemate andibRA333237625klanator metabolism; C5-Branched dibasic acid metabolism; valine, leuxine and isoleacine biosynthesis; pantothemate andibRA330237626bylonyntasisibranot metabolism; C5-Branched dibasic acid metabolism; valine, leuxine and isoleacine biosynthesis; p	nadA	1.36410938	nicotinate and nicotinamide metabolism	
pgW1.40831967I.Anine exportergPQ145048870kycrophospholipid metabolismgPQ145745880kycrophospholipid metabolismgPQ1.37578500kycrophospholipid metabolism dyvine, serine and thronine metabolism; lipoic acid metabolismgPQ11.3794130kycrophospholipid metabolism; dyvine, serine and thronine metabolism; lipoic acid metabolismgPQ11.7578730value, secine and dicaborylate metabolism; dyvine, serine and thronine metabolism; lipoic acid metabolismdPA1.7578730value, secine and dicaborylate metabolism; value, leucine and soleucine biosynthesisdPA1.78174700gyvine serine and thronine metabolism; value, leucine and soleucine biosynthesisdPA1.78174700fuctos and manosemdPA1.7817400fuctos and manosemdPA1.787930241alanico. suparata and glutamate metabolism; arginine and proline metabolismdPA1.7817400fuctos and manosemdPA2.93664850mino sugar and nucleotide sugar metabolism; arginine and proline metabolism; value, leucine and isoleucine biosynthesisnAref2.93664850sincos and metabolism; GS-Branchel dibasic acid metabolism; value, leucine and isoleucine biosynthesis paratothemate and CobiosynthesisnBrincos and manosemsincos and metabolism; GS-Branchel dibasic acid metabolism; value, leucine and soleucine biosynthesis paratothemate and CobiosynthesisnBrincos and metabolism; GS-Branchel dibasic acid metabolism; value, leucine and isoleucine biosynthesis paratothemate and CobiosynthesisnBrincos and metabolism; GS-Branchel dibasic acid metabolism; va	glpT	1.367466661	glycerol-3-phosphate transporter	
No. Proceeding gPQ 1.456168876 gyccrophospholipid metabolism gPD 1.47785806 gyccrophospholipid metabolism nmM 1.49014699 Nacetylneuraninate epimerase gerH 1.5078413 glyosylate and dicarboxylate metabolism; glycine, serine and threenine metabolism; lipoic acid metabolism drA 1.7578503 valite, leucine and isoleucine biosynthesis partothenate and CoA biosynthesis drA 1.84234762 glych, serine and threenine metabolism; valine, leucine and isoleucine biosynthesis drA 1.84234762 glych, serine and platmate metabolism; valine, leucine and isoleucine biosynthesis drA 1.81297687 fructose and nannoe metabolism; valine, leucine and platmate metabolism; valine, leucine and isoleucine biosynthesis mRA 1.80976801 almine sagartate and glutamate metabolism; valine, leucine and soleucine biosynthesis mRA 2.09366081 almine sugar and nucleotide sugar metabolism; valine, leucine and isoleucine biosynthesis mRA 2.06747051 glycheuraninate and CoA biosynthesis ibRA 2.66747251 butanoate metabolism; valine, leucine and isoleucine biosynthesis pantothemate and CoA biosynthesis jyclef 3.23376250 butanoate me	sucD	1.382561251	citrate cycle (TCA cycle); propanoate metabolism; C5-Branched dibasic acid metabolism	
ArrowBecarbospholiplid metabolismgpDm14.75785806gp/cerophospholiplid metabolismnmAM1.493614099N-accephospholiplid metabolismgpAH15074113glyoxylate and dicarboxylate metabolism; glycine, serine and threonine metabolism; lipoic acid metabolismgpAH1.75787030valine, leucine and isoleucine biosynthesis pantothenate and CoA biosynthesisdirA1.784324762glycine, serine and threonine metabolism; valine, leucine and isoleucine biosynthesisduX1.812119174D-Amino acid metabolismgpDM1.819297687frectose and manose metabolism; arginine and proline metabolismgrIA1.85793021alanine, sapartate and glutamate metabolism; arginine and proline metabolismmarK2.0346603amino sugar and nucleotide sugar metabolism; arginine and proline metabolismmarK2.0346604amino sugar and nucleotide sugar metabolism; arginine and isoleucine degradation; valine, leucine and isoleucine biosynthesis;marK2.0346605amino sugar and nucleotide sugar metabolism; valine, leucine and isoleucine biosynthesis;marK2.0346605amino sugar and nucleotide sugar metabolism; valine, leucine and isoleucine biosynthesis;marK2.0466705cysteine and methonine metabolism; valine, leucine and isoleucine biosynthesis;marK2.0576205cysteine and methonine metabolism; valine, leucine and isoleucine biosynthesis; pantothenate and CoA biosynthesismarK2.06740271bicanoare metabolism; C5-Branched dibasic acid metabolism; valine, leucine and isoleucine biosynthesis; pantothenate and CoA biosynthesisgkE5.08915048 <td>ygaW</td> <td>1.400831967</td> <td>L-Alanine exporter</td>	ygaW	1.400831967	L-Alanine exporter	
nahM149614699Nacayheuraninate epimerasege/H150784130glysylate and dicarboxylate metabolism; glycine, serine and threonine metabolism; lipcic acid metabolismfib/D175787503valine, leacine and isoleucine biosynthesis pantothenate and CoA biosynthesisfib/A174124762glycine, serine and threonine metabolism; valine, leucine and isoleucine biosynthesisda/AX1821191740JoAmino acid metabolismafa/D1819976801fuctose and manose metabolism; arginine and proline metabolismarbitom183930281alaine, aspartate and glutamate metabolism; arginine and proline metabolismnark2039366883anino sugar and nucleotide sugar metabolism; arginine and proline metabolismnark2039366840provate metabolism; arginine and proline metabolism;nark203767530grycute metabolism; CS-Branched dibasic acid metabolism; valine, leucine and isoleucine biosynthesis; pantothenate andnark204740771butmoate metabolism; CS-Branched dibasic acid metabolism; valine, leucine and isoleucine biosynthesis; pantothenate andnb/hoalso21357625butmoate metabolism; CS-Branched dibasic acid metabolism; valine, leucine and isoleucine biosynthesis; pantothenate andnb/hoalso21357626butmoate metabolism; CS-Branched dibasic acid metabolism; valine, leucine and isoleucine biosynthesis; pantothenate andnb/hoslos21357626glosyntheaisglosta unitazione; CS-Branched dibasic acid metabolism; valine, leucine and isoleucine biosynthesis; pantothenate andnb/hoslos21357626glosyntae and candosylate metabolism; CS-Branched dibasic acid metabolism; valine, leucine an	glpQ	1.436168876	glycerophospholipid metabolism	
geH15078413flyoxylat and dicarboxylat metabolism; glycine, serine and threonine metabolism; lipoic acid metabolismlibD1757875030Value, leucine and isoleucine biosynthesis pantothenate and CoA biosynthesislibA175187503Glycine, serine and threonine metabolism; value, leucine and isoleucine biosynthesisdidX1812119174D-Amino acid metabolismshD181297870Fuctose and manose metabolism; value, leucine and isoleucine biosynthesispuA18593024danine, aspartate and glutamate metabolism; arginine and proline metabolismnuRK209366030amino sugar and nucleotide sugar metabolismnuRE1207682050gyntura metabolism; value, leucine and isoleucine degradation; value, leucine and isoleucine biosynthesis; pantobienate and CoA biosynthesish/B-M20476771koitena emetabolism; CS-Branched dibasic acid metabolism; value, leucine and isoleucine biosynthesis; pantothenate and CoA biosynthesish/B-M308021082butinoate metabolism; CS-Branched dibasic acid metabolism; value, leucine and isoleucine biosynthesis; pantothenate and CoA biosynthesish/B-M308021082butinoate metabolism; CS-Branched dibasic acid metabolism; value, leucine and isoleucine biosynthesis; pantothenate and CoA biosynthesisstersterstergl-G5.80951504gloxylat and dicarboxylate metabolism; value, leucine and isoleucine biosynthesis; pantothenate metabolism; coa biosynthesisgl-G5.80951504gloyolate and dicarboxylate metabolism; gloxylate and dicarboxylate metabolism; gloxylate and dicarboxylate metabolism; gloxylate and dicarboxylate metabolism; gloxylate and dic	glpD	1.473785806	glycerophospholipid metabolism	
iDD177578750valine, lencine and isoleucine biosynthesis pantothenate and CoA biosynthesisiiAA1754324762glycine, serine and threonine metabolism; valine, leucine and isoleucine biosynthesisiiAA1812119174D-Amino acid metabolismarDD1819297687fructose and mannose metabolism; arginine and proline metabolismputA1857930281alanine, aspartate and glutamate metabolism; arginine and proline metabolismnarK2039366083amino sugar and nucleotide sugar metabolismanaRE2076864669amino sugar and nucleotide sugar metabolismine B2.016767205gysteine and metiabolism; valine, leucine and isoleucine degradation; valine, leucine and isoleucine biosynthesis;ib/E2.167676205gysteine and metiabolism; CS-Branched dibasic acid metabolism; valine, leucine and isoleucine biosynthesis; pantothenate and CoA biosynthesisib/RA3.32537626blutanoate metabolism; CS-Branched dibasic acid metabolism; valine, leucine and isoleucine biosynthesis; pantothenate and CoA biosynthesisib/RA3.3253765blutanoate metabolism; CS-Branched dibasic acid metabolism; valine, leucine and isoleucine biosynthesis; pantothenate and CoA biosynthesisib/RA3.04021082gystate and dicarbosylate metabolism; valine, leucine and isoleucine biosynthesis; pantothenate and CoA biosynthesisib/RA3.8053754glystate and dicarbosylate metabolism; valine, leucine and isoleucine biosynthesis; pantothenate and CoA biosynthesisib/RA5.80591504glystate and dicarbosylate metabolism; valine, leucine and isoleucine biosynthesis; pantothenate and CoA biosynthesisib/RA5.80591504	nanM	1.493614699	N-acetylneuraminate epimerase	
iAAI.78432/762glycine, serine and threonine metabolism; valine, leucine and isoleucine biosynthesisdadXI.8121174D-Anino acid metabolismarDI.81927687Fractose and manose metabolism; arginine and proline metabolismputAI.85790281alanine, aspartate and glutamate metabolism; arginine and proline metabolismnmK0.20936083alanino sagar and nucleotide sugar metabolism; arginine and proline metabolismnmR0.207864604anino sagar and nucleotide sugar metabolism; arginine and jsoleucine degradation; valine, leucine and isoleucine biosynthesis;ib/B0.207864609gysteine and metholism; valine, leucine and isoleucine degradation; valine, leucine and isoleucine biosynthesis;ib/B2.80747500gysteine and metholism; valine, leucine and isoleucine biosynthesis; pantothenate andib/B3.2032752butanoste metabolism; C3-Branched dibasic acid metabolism; valine, leucine and isoleucine biosynthesis; pantothenate andib/B3.0021082butanoste metabolism; C3-Branched dibasic acid metabolism; valine, leucine and isoleucine biosynthesis; pantothenate andib/B3.0021082butanoste metabolism; C3-Branched dibasic acid metabolism; valine, leucine and isoleucine biosynthesis; pantothenate andib/B5.80517450gysteinat diadrosylate metabolism; valine, leucine and isoleucine biosynthesis; pantothenate andib/B5.80517450gysteinat diadrosylate metabolism; valine, leucine and isoleucine biosynthesis; pantothenate andib/B5.80517450gysteinat diadrosylate metabolism; valine, leucine and isoleucine biosynthesis; pantothenate andib/B5.90517461gystein	gcvH	1.5078413	glyoxylate and dicarboxylate metabolism; glycine, serine and threonine metabolism; lipoic acid metabolism	
dwlX1812119174D-Amino acid metabolism <i>avD</i> 1819297687fructose and manose metabolism <i>pulA</i> 1839297687alanine, aspartate and glutamate metabolism; arginine and proline metabolism <i>pulA</i> 1837930281alanine, aspartate and glutamate metabolism; arginine and proline metabolism <i>nanK</i> 2039366083amino sugar and nucleotide sugar metabolism <i>nanE</i> 2076864669amino sugar and nucleotide sugar metabolism <i>nanE</i> 2076864669amino sugar and nucleotide sugar metabolism; <i>ibR</i> 2.6476205cysteine and methionine metabolism; valine, leucine and isoleucine degradation; valine, leucine and isoleucine biosynthesis; <i>ibR</i> 2.80747795N-acceylneuraminate anomerase <i>ibrA</i> 3.302537625butanoate metabolism; CS-Branched dibasic acid metabolism; valine, leucine and isoleucine biosynthesis; pantothenate and CA biosynthesis <i>ibrA</i> 3.0021082butanoate metabolism; CS-Branched dibasic acid metabolism; valine, leucine and isoleucine biosynthesis; pantothenate and CA biosynthesis <i>stut. phase</i> stutoate metabolism; CS-Branched dibasic acid metabolism; valine, leucine and isoleucine biosynthesis; pantothenate and CA biosynthesis <i>stub</i> stutoate metabolism; CS-Branched dibasic acid metabolism; valine, leucine and isoleucine biosynthesis; pantothenate and CA biosynthesis <i>stub</i> stutoate metabolism; CS-Branched dibasic acid metabolism; valine, leucine and isoleucine biosynthesis; pantothenate and CA biosynthesis <i>stub</i> stutoate metabolism; CS-Branched dibasic acid metabolism; valine, leucine and isoleucine biosynthesis; pantothenate and CA biosynthesis <i>stub</i> stutoate m	ilvD	1.775787503	valine, leucine and isoleucine biosynthesis; pantothenate and CoA biosynthesis	
nD1819297687Fuctore and manone metabolismpuRA185790280alanine, asparate and glutamate metabolism; arginine and proline metabolismnarK20396680alinio, sagar and nucleotide sugar metabolismldD204837543pruvate metabolismmRE207686469alinio, sugar and nucleotide sugar metabolismin/E2.61767205cysteine and methionine metabolism; valine, leucine and isoleucine begradation; valine, leucine and isoleucine biosynthesis;i/B2.64742771butnote metabolism; CS-Branched dibasic acid metabolism; valine, leucine and isoleucine biosynthesis; pantothenate and CA biosynthesisi/BA3.0021082butnote metabolism; CS-Branched dibasic acid metabolism; valine, leucine and isoleucine biosynthesis; pantothenate and CA biosynthesisi/BA3.0021082butnote metabolism; CS-Branched dibasic acid metabolism; valine, leucine and isoleucine biosynthesis; pantothenate and CA biosynthesisi/BA3.0021082butnote metabolism; CS-Branched dibasic acid metabolism; valine, leucine and isoleucine biosynthesis; pantothenate and CA biosynthesisi/BA3.0021082butnote metabolism; CS-Branched dibasic acid metabolism; valine, leucine and isoleucine biosynthesis; pantothenate and CA biosynthesisi/BA5.00810408glosylate and dicarboxylate metabolism; Valine, leucine and isoleucine biosynthesis; pantothenate and CA biosynthesisi/BA5.09810508glosylate and dicarboxylate metabolism; valine, leucine and isoleucine biosynthesisi/BA5.09810508glosylate and dicarboxylate metabolism; valine, leucine and isoleucine biosynthesisi/BA5.09810508glosolate utization <td>ilvA</td> <td>1.784324762</td> <td>glycine, serine and threonine metabolism; valine, leucine and isoleucine biosynthesis</td>	ilvA	1.784324762	glycine, serine and threonine metabolism; valine, leucine and isoleucine biosynthesis	
pullInstromepull185790281alanine, aspartate and glutamate metabolism; arginine and proline metabolismnank2039366083mino sugar and nucleotide sugar metabolismldD2043637543pyruvate metabolismnanE2076864669anino sugar and nucleotide sugar metabolismib/E2016762050cysteine and methionine metabolism; valine, leucine and isoleucine biosynthesis; pantothenate and CoA biosynthesisib/E264762713butanote metabolism; S-Branched dibasic acid metabolism; valine, leucine and isoleucine biosynthesis; pantothenate andib/R330537625butanote metabolism; CS-Branched dibasic acid metabolism; valine, leucine and isoleucine biosynthesis; pantothenate andib/R3406210862butanote metabolism; CS-Branched dibasic acid metabolism; valine, leucine and isoleucine biosynthesis; pantothenate andib/R340521082butanote metabolism; CS-Branched dibasic acid metabolism; valine, leucine and isoleucine biosynthesis; pantothenate andib/R340521082butanote metabolism; CS-Branched dibasic acid metabolism; valine, leucine and isoleucine biosynthesis; pantothenate andib/R5.0801087giovalate and dicarboxylate metabolism; valine, leucine and isoleucine biosynthesis; pantothenate andib/R5.08018463giovalate and dicarboxylate metabolismib/R5.08018463giovalate and dicarboxylate metabolismib/R5.08018463giovalate and dicarboxylate metabolismib/R5.08018463giovalate and dicarboxylate metabolismib/R5.08018463giovalate and dicarboxylate metabolismib/R5.0801	dadX	1.812119174	D-Amino acid metabolism	
AndConstruction of the construction of th	srlD	1.819297687	fructose and mannose metabolism	
IdD2.043637543pyruvate metabolismnanE2.076864669amino sugar and nucleotide sugar metabolismib/E2.16767205cysteine and methoinine metabolism; valine, leucine and isoleucine degradation; valine, leucine and isoleucine biosynthesis; pantothenate and CoA biosynthesisib/E2.64746271butanoate metabolism; C5-Branched dibasic acid metabolism; valine, leucine and isoleucine biosynthesis; pantothenate and CoA biosynthesisib/B2.806747795N-acetylneuraminate anomeraseib/G3.32537625butanoate metabolism; C5-Branched dibasic acid metabolism; valine, leucine and isoleucine biosynthesis; pantothenate and CoA biosynthesisib/R3.406210862butanoate metabolism; C5-Branched dibasic acid metabolism; valine, leucine and isoleucine biosynthesis; pantothenate and CoA biosynthesisib/R3.406210862butanoate metabolism; C5-Branched dibasic acid metabolism; valine, leucine and isoleucine biosynthesis; pantothenate and CoA biosynthesisib/R5.809515048glyoxylate and dicarboxylate metabolismglcD-5.80308467glyoxylate and dicarboxylate metabolismglcA-3.84055795glycolate permeaseglcG-3.437418583glycolate utilizationglcB-3.040428269pyruvate metabolism; glyoxylate and dicarboxylate metabolismglcF-2.970438825D-allose transport ATP-binding proteinglcF-2.6863743glyoxylate and dicarboxylate metabolism	putA	1.857930281	alanine, aspartate and glutamate metabolism; arginine and proline metabolism	
nankinformationnank2.076864699amino sugar and nucleotide sugar metabolismibkE2.167676205cysteine and methionine metabolism; valine, leucine and isoleucine degradation; valine, leucine and isoleucine biosynthesis; antothenate and CoA biosynthesisibkB2.64746271charaote metabolism; CS-Branched dibasic acid metabolism; valine, leucine and isoleucine biosynthesis; pantothenate and CoA biosynthesisibkB2.806747795N-acetylneuraminate anomeraseibkG3.32537625butanoate metabolism; CS-Branched dibasic acid metabolism; valine, leucine and isoleucine biosynthesis; pantothenate and CoA biosynthesisibkNa.40621080butanoate metabolism; CS-Branched dibasic acid metabolism; valine, leucine and isoleucine biosynthesis; pantothenate and CoA biosynthesisgkE5.80931504gloxylate and dicarboxylate metabolism; valine, leucine and isoleucine biosynthesis; pantothenate and coA biosynthesisgkG3.34042269glyoxylate and dicarboxylate metabolismgkA3.94042269glyoxylate and dicarboxylate metabolismgkA3.94042269pruvate metabolism; glyoxylate and dicarboxylate metabolismgkA3.940428269pruvate metabolism; glyoxylate and dicarboxylate metabolismgkA3.940428269pruvate metabolism; glyoxylate and dicarboxylate metabolismgkA3.940428269p	nanK	2.039366083	amino sugar and nucleotide sugar metabolism	
InterfactInterfactoriailvE2.167676205cystein and methionine metabolism; valine, leucine and isoleucine degradation; valine, leucine and isoleucine biosynthesis; pantothenate and CoA biosynthesisilvB2.647462771butanoate metabolism; CS-Branched dibasic acid metabolism; valine, leucine and isoleucine biosynthesis; pantothenate and CoA biosynthesisyhcH2.806747795N-acetylneuraminate anomeraseilvG3.32537625butanoate metabolism; CS-Branched dibasic acid metabolism; valine, leucine and isoleucine biosynthesis; pantothenate and CoA biosynthesisilvN3.406210862butanoate metabolism; CS-Branched dibasic acid metabolism; valine, leucine and isoleucine biosynthesis; pantothenate and CoA biosynthesisgkE15.809515048glyoxylate and dicarboxylate metabolismgkA-5.50830467glyoxylate and dicarboxylate metabolismgkG-3.437418583glycolate permeasegkG-3.437418583glycolate utilizationgkA-3.437418583pryrvate metabolism; glyoxylate and dicarboxylate metabolismgkA-3.64032269pryrvate metabolism; glyoxylate and dicarboxylate metabolismgkA-2.97043825D-allose transport ATP-binding proteingkF-2.6683745glyoxylate and dicarboxylate metabolism	lldD	2.043637543	pyruvate metabolism	
indexpantothenate and CoA biosynthesisilvB2.647462771butanoate metabolism; C5-Branched dibasic acid metabolism; valine, leucine and isoleucine biosynthesis; pantothenate and coA biosynthesisyhcH2.806747795N-acetylneuraninate anomeraseilvG3.32537625butanoate metabolism; C5-Branched dibasic acid metabolism; valine, leucine and isoleucine biosynthesis; pantothenate and coA biosynthesisilvN3.406210862butanoate metabolism; C5-Branched dibasic acid metabolism; valine, leucine and isoleucine biosynthesis; pantothenate and coA biosynthesisstat.phse-glcE5.809515048glyoxylate and dicarboxylate metabolismglcA5.508308467glyoxylate and dicarboxylate metabolismglcG-3.4305795glycolate permeaseglcA3.40428269pruvate metabolism; glyoxylate and dicarboxylate metabolismglcB-3.040428269pruvate metabolism; glyoxylate and dicarboxylate metabolismglcA-2.970438825C-allose transport ATP-binding proteinglcA-2.80837430glyoxylate and dicarboxylate metabolism	nanE	2.076864669	amino sugar and nucleotide sugar metabolism	
IndexCoA biosynthesisyhcH2.806747795N-acetylneuraminate anomeraseilvG3.332537625butanoate metabolism; C5-Branched dibasic acid metabolism; valine, leucine and isoleucine biosynthesis; pantothenate and CoA biosynthesisilvN3.406210862butanoate metabolism; C5-Branched dibasic acid metabolism; valine, leucine and isoleucine biosynthesis; pantothenate and CoA biosynthesisstat. phasestat. phaseglcE-5.809515048glyoxylate and dicarboxylate metabolismglcD-5.508308467glyoxylate and dicarboxylate metabolismglcA-3.84055795glycolate permeaseglcB-3.040428269glyoclate utilizationglcA-3.040428269D-allose transport ATP-binding proteinglcF-2.86083743glyoxylate and dicarboxylate metabolism	ilvE	2.167676205		
AImage: Constraint of the constraint of t	ilvB	2.647462771		
InterfaceCoA biosynthesisilvN3.406210862butanoate metabolism; C5-Branched dibasic acid metabolism; valine, leucine and isoleucine biosynthesis; pantothenate and CoA biosynthesisstat. phaseglcE-5.809515048glyoxylate and dicarboxylate metabolismglcD-5.508308467glyoxylate and dicarboxylate metabolismglcA-3.84055795glycolate permeaseglcG-3.437418583glycolate permeaseglcA-3.040428269pyruvate metabolism; glyoxylate and dicarboxylate metabolismglcA-2.970438825D-allose transport ATP-binding proteinglcF-2.686837435glyoxylate and dicarboxylate metabolism	yhcH	2.806747795	N-acetylneuraminate anomerase	
CoA biosynthesisstat. phaseglcE-5.809515048glyoxylate and dicarboxylate metabolismglcD-5.508308467glyoxylate and dicarboxylate metabolismglcA-3.84055795glycolate permeaseglcG-3.437418583glycolate utilizationglcB-3.040428269pyruvate metabolism; glyoxylate and dicarboxylate metabolismglcF-2.97043825D-allose transport ATP-binding protein	ilvG	3.332537625		
glc-5.809515048glyoxylate and dicarboxylate metabolismglcD-5.508308467glyoxylate and dicarboxylate metabolismglcA-3.84055795glycolate permeaseglcG-3.437418583glycolate utilizationglcB-3.040428269pyruvate metabolism; glyoxylate and dicarboxylate metabolismglcA-2.970438825D-allose transport ATP-binding proteinglcF-2.686837435glyoxylate and dicarboxylate metabolism	ilvN	3.406210862		
glcD-5.508308467glyoxylate and dicarboxylate metabolismglcA-3.84055795glycolate permeaseglcG-3.437418583glycolate utilizationglcB-3.040428269pyruvate metabolism; glyoxylate and dicarboxylate metabolismglcF-2.970438825D-allose transport ATP-binding proteinglcF-2.686837435glyoxylate and dicarboxylate metabolism	stat. phase			
glcA-3.84055795glycolate permeaseglcG-3.437418583glycolate utilizationglcB-3.040428269pyruvate metabolism; glycxylate and dicarboxylate metabolismglcF-2.970438825D-allose transport ATP-binding proteinglcF-2.666837435glycxylate and dicarboxylate metabolism	glcE	-5.809515048	glyoxylate and dicarboxylate metabolism	
glcG -3.437418583 glycolate utilization glcB -3.040428269 pyruvate metabolism; glyoxylate and dicarboxylate metabolism alsA -2.970438825 D-allose transport ATP-binding protein glcF -2.686837435 glyoxylate and dicarboxylate metabolism	glcD	-5.508308467	glyoxylate and dicarboxylate metabolism	
glcB -3.040428269 pyruvate metabolism; glyoxylate and dicarboxylate metabolism alsA -2.970438825 D-allose transport ATP-binding protein glcF -2.686837435 glyoxylate and dicarboxylate metabolism	glcA	-3.84055795	glycolate permease	
alsA -2.970438825 D-allose transport ATP-binding protein glcF -2.686837435 glyoxylate and dicarboxylate metabolism	glcG	-3.437418583	glycolate utilization	
glcF -2.686837435 glyoxylate and dicarboxylate metabolism	glcB	-3.040428269	pyruvate metabolism; glyoxylate and dicarboxylate metabolism	
	alsA	-2.970438825	D-allose transport ATP-binding protein	
garP -2.178038147 predicted (D)-galactarate transporter	glcF	-2.686837435	glyoxylate and dicarboxylate metabolism	
	garP	-2.178038147	predicted (D)-galactarate transporter	

(Continued)

TABLE 1 Continued

Gene name	log2- fold change	Pathway/function ^{82–84}	
stat. phase			
thrC	-2.009914989	glycine, serine and threonine metabolism; vitamin B6 metabolism	
thrB	-1.883274845	glycine, serine and threonine metabolism	
thrA	-1.856342407	glycine, serine and threonine metabolism; cysteine and methionine metabolism; lysine biosynthesis; monobactam biosynthesis	
tdcG	-1.747142565	glycine, serine and threonine metabolism; cysteine and methionine metabolism	
agaZ	-1.742650224	galactose metabolism	
alsB	-1.728052629	D-allose transporter subunit	
galS	-1.637606696	transcriptional repressor and galactose ultrainduction factor	
garD	-1.620616567	ascorbate and aldarate metabolism	
srlA	-1.61111755	fructose and mannose metabolism	
ybhC	-1.567162144	pentose and glucuronate interconversions	
mglB	-1.542837699	D-galactose-binding periplasmic protein precursor	
mglA	-1.531637382	ABC-type D-galactose transporter	
asnA	-1.500124244	alanine, aspartate and glutamate metabolism; cyanoamino acid metabolism	
ssuB	-1.413738896	sulfur metabolism	
srlD	-1.38914946	fructose and mannose metabolism	
galE	-1.350506556	galactose metabolism; amino sugar and nucleotide sugar metabolism; O-Antigen nucleotide sugar biosynthesis	
mglC	-1.329707605	galactoside transport system permease protein	
melA	-1.18645874	galactose metabolism; glycerolipid metabolism; sphingolipid metabolism	
asnB	-1.065620685	alanine, aspartate and glutamate metabolism	
cdaR	-1.061008612	carbohydrate diacid regulator	
lacZ	-1.015924833	galactose metabolism; sphingolipid metabolism; other glycan degradation	
yahN	-1.003789478	amino acid exporter	
adhP	1.015337508	glycolysis; gluconeogenesis; pyruvate metabolism; fatty acid degradation; tyrosine metabolism; chloroalkane and chloroalkene degradation; naphthalene degradation	
guaB	1.019960645	purine metabolism	
ilvA	1.074184986	glycine, serine and threonine metabolism; valine, leucine and isoleucine biosynthesis	
aceK	1.192060758	isocitrate dehydrogenase kinase/phosphatase	
ilvB	1.778668589	butanoate metabolism; C5-Branched dibasic acid metabolism; valine, leucine and isoleucine biosynthesis; pantothenate and CoA biosynthesis	
mgtS	1.992512123	Mg2*-import associated protein	
ilvG	2.430932647	butanoate metabolism; C5-Branched dibasic acid metabolism; valine, leucine and isoleucine biosynthesis; pantothenate and CoA biosynthesis	
ilvN	2.670495316	butanoate metabolism; C5-Branched dibasic acid metabolism; valine, leucine and isoleucine biosynthesis; pantothenate and CoA biosynthesis	
mgtA	2.724809679	Mg2 ⁺ -importing ATPase	

metabolism. The yghJ (*sslE*) gene, for example, codes for a metalloprotease contributing to mucin degradation in the intestinal tract or the bladder (Nesta et al., 2014). The most strongly downregulated genes were linked to glycolate utilization

(*glcDEFGBA*). Additionally, genes that are involved in D-allose transport (*alsAB*), galactarate metabolism (*garPD* and *cdaR*), galactose metabolism (*mglABC*, *lacZ*, *melA*, *agaZ* and *galES*), sorbitol utilization (*srlAD*), D-serine metabolism (*tdcG*) and

Gene name	log2- fold change	Pathway/ function ^{82–84}
lag phase		
fliN	-2.453087846	bacterial chemotaxis; flagellar assembly
flgC	-2.370643137	flagellar assembly
fliG	-2.154193018	bacterial chemotaxis; flagellar assembly
fliA	-1.967650727	biofilm formation; flagellar assembly
fliP	-1.934071506	flagellar assembly
flgG	-1.89377638	flagellar assembly
fliE	-1.817157817	flagellar assembly
fliO	-1.802383017	flagellar assembly
flgN	-1.76655253	flagellar assembly
flgH	-1.748868638	flagellar assembly
flgB	-1.704583646	flagellar assembly
fliM	-1.650792441	bacterial chemotaxis; flagellar assembly
fliL	-1.611497848	flagellar assembly
flhB	-1.518230416	flagellar assembly
flgA	-1.464314687	flagellar assembly
flgD	-1.426698341	flagellar assembly
flgI	-1.32985639	flagellar assembly
fliZ	-1.324136977	biofilm formation; flagellar assembly
fliI	-1.274724031	flagellar assembly
flhA	-1.24886028	flagellar assembly
flgE	-1.199949551	flagellar assembly
fliF	-1.178707702	flagellar assembly
exp. phase		
bssS	1.02819806	biofilm regulator; TA system
stat. phase		
sfaX	1.107129346	transcriptional regulator; S- fimbrial assembly
C terminal part of outer membrane F1C fimbrial usher protein SfaF	1.280095448	S-fimbrial assembly
sfaS	1.317340212	secretion system; S- fimbrial assembly
sfaG	1.364663339	adhesion; S- fimbrial assembly

TABLE 2 Differentially expressed genes in *E. coli* 83972 *attB::lsr* relative to *E. coli* 83972 associated with motility, biofilm formation and adhesion.

(Continued)

TABLE 2 Continued

Gene name	log2- fold change	Pathway/ function ^{82–84}
stat. phase		
sfaY	1.429358699	transcriptional regulator; S- fimbrial assembly
sfaH	1.475091904	secretion system; S- fimbrial assembly

sulfur utilization (*ssuB*) were significantly downregulated, too. Furthermore, genes associated with L-threonine (*thrABC*) and asparagine (*asnAB*) synthesis, as well as three genes that code for components of a putative oxidoreductase (*ydhYVX*) were also downregulated.

3.3 Reintroduction of the *lsr* locus reduces competitiveness *in vitro*

As the majority of differentially regulated genes affect the bacterial metabolism, we hypothesized that E. coli 83972 attB::lsr might have a growth defect when compared to the wild type strain 83972. Therefore, we analyzed and compared the growth behavior of both strains under aerobic and anaerobic conditions in LB (Figure 4) and pooled human urine (Supplementary Figure S3). In all conditions tested, E. coli 83972 attB::lsr had a significantly longer lag phase (Figures 4B, E; Supplementary Figures S3B, E) and a significantly higher doubling time than parental strain 83972 (Figures 4C, F; Supplementary Figures S3C, F). Next, we performed a growth competition experiment with E. coli 83972 and E. coli 83972 attB::lsr to test this phenotype for its biological relevance. To be able to differentiate between both strains by fluorescence microscopy, we introduced the plasmid pLS1 (cfp under the control of the stationary phase-dependent dps promoter) into E. coli 83972 attB::lsr and the plasmid pLS2 (identical to pLS1 on the nucleotide level, but cfp is replaced by yfp) into E. coli 83972. First, we mimicked bottleneck situations for which we mixed these two strains in a 1:1 ratio and grew the competing strains for 3 h, followed by a subsequent dilution into fresh medium. This cycle was repeated three times. After 3 h of growth, the proportion of E. coli 83972 (pLS2) increased from $52 \pm 3.7\%$ to $72 \pm 13.3\%$ while further increasing to $97 \pm 0.8\%$ after three transfers (Figure 5A). After 3 h of growth in pooled human urine, the proportion of E. coli 83972 (pLS2) rose from 49 \pm 6.1% to 61 \pm 2.1% while making up 79 \pm 1.1% after three serial passages (Supplementary Figure S4A). We also tested for the long-term competitiveness of both strains. We observed that the proportion of E. coli 83972 (pLS2) significantly rose from 51 \pm 1.7% to 75 \pm 0.3% in LB after 24 h of direct competition (Figure 5B). Within the following 48 h, the proportion of E. coli 83972 (pLS2) remained unchanged. In pooled human urine, we saw that the proportion of the wild type strain

TABLE 3 Differentially expressed genes in *E. coli* 83972 *attB::lsr* relative to *E. coli* 83972 associated with growth.

Gene name	log2- fold change	Pathway/function ^{82–84}
lag phase		
trnK3	-1.936591094	aminoacyl-tRNA biosynthesis
trnK4	-1.904947039	aminoacyl-tRNA biosynthesis
trnV3	-1.772558046	aminoacyl-tRNA biosynthesis
trnV5	-1.713113393	aminoacyl-tRNA biosynthesis
trnV4	-1.708725917	aminoacyl-tRNA biosynthesis
trnK1	-1.324258994	aminoacyl-tRNA biosynthesis
trnK2	-1.217243916	aminoacyl-tRNA biosynthesis
trnK5	-1.150592884	aminoacyl-tRNA biosynthesis
nrdF	1.0340548	deoxyribonucleotide biosynthesis
nrdH	1.139857909	deoxyribonucleotide biosynthesis
nrdE	1.269219097	deoxyribonucleotide biosynthesis
nrdI	1.30323686	deoxyribonucleotide biosynthesis
exp. phase		
trnK3	-1.676797599	aminoacyl-tRNA biosynthesis
trnK4	-1.60586492	aminoacyl-tRNA biosynthesis
trnV4	-1.238175595	aminoacyl-tRNA biosynthesis
trnV5	-1.23717919	aminoacyl-tRNA biosynthesis
trnV3	-1.237008793	aminoacyl-tRNA biosynthesis
pyrE	-1.194313829	pyrimidine de novo biosynthesis
cydB	-1.006975401	cytochrome d ubiquinol oxidase subunit
stat. phase		
rpsS	-1.193234994	component of 30S ribosomal subunit
dbpA	-1.087482054	ribosome biogenesis
ybjG	1.166583523	peptidoglycan biosynthesis; teichoic acid biosynthesis

significantly rose from $48 \pm 2.8\%$ to $67 \pm 2.7\%$ after 72 h of competition (Supplementary Figure S4B).

3.4 Reintroduction of *lsr* locus or deletion of *ybhC* leads to a lower resistance against oxidative stress

To test for resistance to oxidative stress, we added different concentrations of H_2O_2 to low bacterial numbers of the *E. coli* strains 83972, 83972 $\Delta ybhC$ and 83972 *attB::lsr* and analyzed their growth behavior. We observed that the length of the lag phase was significantly longer for *E. coli* 83972 after the addition of 160 μ M H_2O_2 as compared to the water control, while the addition of 40 μ M or 100 μ M did not lead to a significantly longer lag phase. In the case

TABLE 4 Differentially expressed genes in *E. coli* 83972 *attB::lsr* relative to *E. coli* 83972 associated with stress response.

gene name	log2- fold change	pathway/function ^{82–84}		
lag phase				
cpxP	-1.012637356	chaperones and folding catalysts; resistance to extracytoplasmic stress		
exp. phas	e			
sodA	-1.132854292	superoxide dismutase		
усjX	1.056824975	induced under nitrogen starvation		
inaA	1.254017352	pH-inducible protein involved in stress response		
ibpB	2.077026895	heat shock protein		
stat. phas	stat. phase			
ydh Y	-1.674500305	predicted ferredoxin-like protein		
ydhX	-1.481012743	predicted ferredoxin-like protein		
ydhV	-1.131341197	aldehyde ferredoxin oxidoreductase		
marB	1.133272934	multiple antibiotic resistance protein		
ymdF	1.250735552	stress-induced protein		
ycfR	1.262325635	stress-response protein		

of the *E. coli* strains 83972 $\Delta ybhC$ and 83972 *attB::lsr*, on the other hand, already the addition of 100 μ M resulted in significantly longer lag phases as compared to the corresponding water controls (Figure 6). Once the strains entered exponential growth, however, the doubling times were not affected by the initial H₂O₂ stress (Supplementary Figure S5).

3.5 Complementation of *E. coli* strain 83972 with the *lsr* operon results in impaired colonization capacity in the digestive tract of *Galleria mellonella* larvae

Uropathogenic *E. coli* normally have their reservoir in the densely populated intestinal tract, and urinary tract infections usually occur through smear infection with bacteria originating from the intestinal tract. To test whether the presence of a functional *lsr* operon affects the ability of *E. coli* strain 83972, as a degenerate uropathogen, to efficiently colonize a niche that is densely populated by different types of bacteria such as the intestinal tract, we fed *G. mellonella* larvae with a mixture of *E. coli* strain 83972 and its *lsr*-complemented variant in a 1:1 ratio. Quantification after 24 h incubation showed that the *lsr*-positive *E. coli* 83972 variant was found in significantly lower numbers in the digestive tract of the *G. mellonella* larvae than the wild type strain. After 24 hours, the *lsr*-negative wild type *E. coli* 83972 outcompeted its *lsr*-positive complemented counterpart in the digestive tract of *G. mellonella* larvae (Figure 7).

TABLE 5 Remaining differentially expressed genes in *E. coli* 83972 *attB*:: *lsr* relative to *E. coli* 83972.

Gene name	log2- fold change	Pathway/function ^{82–84}		
lag phase				
putative methyltransferase	-2.044036679	-		
antirestriction protein	-1.674016348	-		
yabN	-1.441756062	transcription factor		
yhfG	-1.409124762	TA System		
ycjF	-1.10548474	predicted membrane protein associated with virulence in a murine model		
ymgD	-1.024673712	possibly TA system		
lsrR	6.259241476	transcriptional repressor; <i>lsr</i> locus introduction		
lsrK	6.922763675	AI-2 kinase; <i>lsr</i> locus introduction		
aph	11.20318319	kanamycin resistance gene; <i>lsr</i> locus introduction		
cat	11.59026441	chloramphenicol resistance gene; <i>lsr</i> locus introduction		
exp. phase				
ymgD	-2.028703146	possibly TA system		
hypothetical protein 10	-1.823290623	-		
hypothetical protein 6	-1.662041435	-		
hypothetical protein 8	-1.33921833	-		
yiaD	-1.267749645	putative outer membrane protein		
pmrR	-1.155320974	small regulatory membrane protein		
outer membrane porin protein LC precursor	1.100938115	transporter; pores iron channel		
fxsA	1.275237522	cytoplasmic membrane protein		
ompF	1.328798394	outer membrane protein		
lsrR	8.021393949	transcriptional repressor; <i>lsr</i> locus introduction		
lsrK	8.277667483	AI-2 kinase; <i>lsr</i> locus introduction		
aph	11.13917456	kanamycin resistance gene; <i>lsr</i> locus introduction		
cat	13.30014141	chloramphenicol resistance gene; <i>lsr</i> locus introduction		
stat. phase				
yghJ	-2.038713336	putative lipoprotein		
ујаВ	-1.080319092	peptidyl-lysine N-acetyltransferase		
hypothetical protein 12	-1.031550868	-		
yrbL	1.010712982	-		

(Continued)

TABLE 5 Continued

Gene name	log2- fold change	Pathway/function ^{82–84}
stat. phase		
antirestriction Ral family protein	1.033440867	-
putative colicin immunity protein	1.061726625	-
hypothetical protein 7	1.370170227	-
VapA/VapB family virulence associated protein	1.892144739	-
lsrG	6.851703901	isomerase; lsr locus introduction
lsrC	8.029960122	part of AI-2 transporter; <i>lsr</i> locus introduction
lsrB	8.088569874	AI-2 receptor; <i>lsr</i> locus introduction
lsrF	8.122185059	thiolase; <i>lsr</i> locus introduction
lsrD	8.795794664	part of AI-2 transporter; <i>lsr</i> locus introduction
lsrA	9.402359596	part of AI-2 transporter; <i>lsr</i> locus introduction
lsrK	9.814535263	AI-2 kinase; <i>lsr</i> locus introduction
lsrR	10.53084923	transcriptional repressor; <i>lsr</i> locus introduction
aph	11.52317813	kanamycin resistance gene; <i>lsr</i> locus introduction
cat	13.6273497	chloramphenicol resistance gene; <i>lsr</i> locus introduction

3.6 *E. coli* of the phylogroup B2 are predominantly *lsr*-negative

To obtain an overview of the abundance of the *lsr* locus in the *E*. coli population, we screened all E. coli genomes that were available from the NCBI database concerning their phylogroup and the presence of the full-length lsr locus. In total, we analyzed 32,404 genomes of isolates from the phylogroups A, B1, B2, C, D, E, F, and G. Genomes from isolates of phylogroup B1 accounted for the largest share (29.1%), followed by phylogroup A (28.2%) and phylogroup B2 (18.6%) (Supplementary Table S2). We screened these genomes for the presence of the full-length lsr locus (reference DNA sequence from the E. coli K-12 strain MG1655) in all genomes. The search resulted in 22,259 complete, 1,861 incomplete and 2,400 multiple matches. In 5,884 genomes, we detected no match or a blastn hit length that was shorter than 100 bp (Supplementary Table S3). We found that > 81% of *E. coli* strains belonging to the phylogroups A1, B1, C, D, E, F, or G carry a full-length lsr locus. On the contrary, in > 95% of E. coli isolates belonging to the phylogroup B2, a homologous region smaller than



Restoration of the lsr determinant impairs growth of E. coli 83972. Growth analysis of E. coli strains 83972 and 83972 attB::lsr was done in LB under (A-C) aerobic and (D-F) anaerobic conditions. (A, D) Growth curves over a time span of 1000 min with optical density (OD₆₀₀) measurements every 10 min of E. coli 83972 (black circles) and E. coli 83972 attB::lsr (grey squares). (B, E) Time until the cultures reached the exponential growth phase (lagC). (C, F) Doubling time during the exponential growth phase. Depicted are three biological replicates performed in duplicates each. The starting OD₆₀₀ was 0.01 for both strains. Growth curve analysis was done using AMiGA (Midani et al., 2021). Statistical analysis was performed using an unpaired t-test; values < 0.05 were considered statistically significant (** p<0.01, **** p<0.0001).

100 bp was detected (Figure 8, Supplementary Figure S6A). We analyzed the prevalence of the luxS and tam genes in the E. coli population. The search for the *luxS* genes in the genome collection resulted in 32,301 complete, 22 incomplete, and 62 multiple matches. In 19 genomes, we found no match (Supplementary Table S3). The search for the tam gene, which is located downstream of lsrG resulted in 30,364 complete, 1,679 incomplete, and 181 multiple matches. In 180 genomes, we found no match (Supplementary Table S3). Accordingly, more than 99% of the analyzed E. coli genomes include a full-length luxS gene



FIGURE 5

Restoration of the *lsr* determinant reduces competitiveness in serial passaging of *E. coli* 83972. Competition assays were done by mixing overnight cultures of strains 83972 (pLS2) and 83972 *attB::lsr* (pLS1) in a 1:1 ratio in LB. (A) The cultures were grown and subsequently diluted (1:200) into fresh medium every 3 h. Depicted are the mean values and standard deviations of the ratio analysis of ten microscopic pictures for four biological replicates at the indicated time points. (B) The cultures were grown over a total of 72 h. Depicted are the mean values and standard deviations of the ratio analysis of ten microscopic pictures for three biological replicates at the indicated time points. (B) The cultures were grown over a total of 72 h. Depicted are the mean values and standard deviations of the ratio analysis of ten microscopic pictures for three biological replicates at the indicated time points. Statistical analysis was performed using RM one-way ANOVA (Geisser-Greenhouse correction) with Dunnett's multiple comparison test; values < 0.05 were considered statistically significant (* p<0.05, ** p<0.01, *** p<0.01).

(Supplementary Figure S6B), and > 88% of the analyzed *E. coli* genomes possess a full-length tam gene (Supplementary Figure S6C).

4 Discussion

AI-2-dependent QS was shown to play an essential role in APEC and MPEC strains for virulence, colonization, or resistance (Palaniyandi et al., 2013; Han et al., 2015; Xue et al., 2016; Zuo et al., 2019; Yu et al., 2020; Wang et al., 2021; Helmy et al., 2022). However, except for knowledge about the role of QS-induced biofilm formation in catheter-associated UTIs (Laganenka and Sourjik, 2018; Henly et al., 2021; Lila et al., 2023), little is known about the function of AI-2dependent QS in UTIs. *E. coli* 83972 is naturally *lsr*-negative but *luxS*positive and causes asymptomatic bacteriuria (Medina and Castillo-Pino, 2019). We analyzed this strain's ability to produce, export, import, and phosphorylate AI-2. We found that *E. coli* 83972 produced AI-2, which could be sensed by another *E. coli* strain during co-culture (Figure 2B). The AI-2 production was LuxSdependent, as judged by the inability to induce AI-2-dependent YFP expression in our reporter strain when *luxS* was deleted in *E. coli* 83972



FIGURE 6

Introduction of the *lsr* locus or deletion of *ybhC* negatively affects oxidative stress resistance of *E. coli* 83972. Shown is the time until the bacteria reach the exponential growth phase (lagC) during growth of *E. coli* strains 83972, 83972 *ΔybhC* and 83972 *attB::lsr* in LB. The starting OD₆₀₀ was 0.01 for each strain. Before growth analysis, the strains were challenged with a final H_2O_2 concentration of 40 µM, 100 µM or 160 µM. Water was added as a negative control. LagC was analyzed using AMiGA (Midani et al., 2021). The statistical analysis was performed using ordinary two-way ANOVA with Tukey's multiple comparison test. Only the effect of different H_2O_2 concentrations on the growth of the respective *E. coli* strains was compared (83972, 83972 *ΔybhC* and 83972 *attB::lsr*; simple effect within rows); values < 0.05 were considered statistically significant (** p<0.01, **** p<0.001).



(Figure 2B). However, we observed no AI-2-dependent YFP expression when *E. coli* 83972 $\Delta luxS$ (pMK2) was challenged with extracellular DPD (Figures 2D, E). In comparison, the addition of low concentrations of extracellular DPD to *E. coli* 83972 $\Delta luxS$ (pMK1) has led to a significantly higher YFP expression compared to the water control (Figure 2F). This result was expected since *E. coli* 83972 does not encode LsrK, which is so far the only described kinase that phosphorylates incorporated AI-2 (Pereira et al., 2012). Since AI-2 is initially taken up in an Lsr-independent way by a phosphoenolpyruvate phosphotransferase system, the lack of an active AI-2 kinase would not lead to an AI-2 sequestration inside the cell because unphosphorylated AI-2 is transported back into the extracellular space (Marques et al., 2011; Pereira et al., 2012; Trappetti et al., 2017). When pMK1, a plasmid encoding LsrK, was introduced into *E. coli* 83972, externally



FIGURE 8

The majority of *E. coli* isolates of the phylogroup B2 does not encode an *lsr* locus. Shown is the distribution of 30,004 *E. coli* genomes with respect to their phylogroup (A, B1, B2, C, D, E, F or G) and the presence of the full-length *lsr* locus (*E. coli* K-12 strain MG1655 *lsrRK-lsrACDBFG*; size: 8,673 bp). "Complete" (light grey) equals a blastn match of 8,673 bp, "incomplete" (dark grey) equals a blastn match < 8,673 bp and "< 100 bp" (black) equals a blastn match < 100 bp. added AI-2 was incorporated, phosphorylated, and sequestered inside the cell, while the introduction of pMK2, lacking lsrK, did not lead to AI-2 phosphorylation. These results let us conclude that E. coli 83972 produces AI-2, which can be sensed by other bacteria but cannot process AI-2 itself. This is not unusual, as other bacteria are also known to be unable to sense AI-2 and express luxS only because of its role in the activated methyl cycle (Rezzonico and Duffy, 2008). One example is the uropathogenic Proteus mirabilis strain BB2000, which does not possess a luxP or lsrB homolog but does express luxS (Rezzonico and Duffy, 2008). Furthermore, the deletion of luxS did not lead to altered colonization or pathogenicity of this strain during UTI in a mouse model (Schneider et al., 2002), suggesting that AI-2-dependent QS does not play a role during UTI in this strain. To reintroduce the ability to use AI-2 as a signaling molecule, we integrated the lsr locus into the chromosomal attB site of E. coli 83972 (Figure 2A). Indeed, when E. coli 83972 AluxS attB::lsr (pMK2) was challenged with extracellular DPD, we observed a significantly higher YFP expression as compared to the water control (Figures 2D, E). This result suggests that lsrK is functionally expressed in E. coli 83972 attB::lsr. Additionally, E. coli 83972 attB::lsr could export AI-2, which could be sensed by another E. coli strain in coculture (Figure 2C).

The observation that global gene expression of UPEC strains in vivo during human UTI (hUTI) or murine UTI (mUTI) was more similar to their in vitro gene expression in LB than to their in vitro gene expression in pooled human urine (Frick-Cheng et al., 2020) allows us to assess the importance of lsr-dependent gene expression for colonization of the urinary bladder using our own in vitro RNAseq data in LB. Our transcriptome analysis revealed that the transcriptomes of the E. coli strains 83972 and 83972 attB::lsr were not drastically different during the three growth phases (Supplementary Figure S2). Only 60-72 genes were differentially expressed in E. coli strains 83972 and 83972 attB::lsr with a log2-fold change of higher or lower 1 (Figure 3). By comparing the results of Frick-Cheng and colleagues (Frick-Cheng et al., 2020) to our data, we observed that some genes or operons that were differentially expressed in vivo during hUTI/mUTI relative to in vitro growth in LB, also seem to be affected by AI-2-dependent QS. For example, several genes from the flagellar machinery (flgCFGLM and fliS) were downregulated during mUTI/hUTI as compared to growth in LB (Frick-Cheng et al., 2020). More than 50% of all downregulated genes in E. coli 83972 attB::lsr in the lag phase were linked to the flagellar machinery (Table 2). The link between AI-2-dependent QS and flagellar gene expression was also seen in the EHEC strain 86-24, where the deletion of *luxS* led to a downregulation of flagellar genes (Sperandio et al., 2001), which is contradictory to our results where AI-2-dependent QS seems to repress flagellar gene expression. In UPEC strain CFT073, flagella expression was not crucial for bladder colonization efficiency, whereas the loss of flagellar genes was a disadvantage during bladder colonization (Lane et al., 2005). During UTI, the flagella induce a Toll-like receptor-dependent immune response and, thus, inflammation (Subashchandrabose and Mobley, 2015; Acharya et al., 2019). However, since the *flhDC* genes coding for the master regulator of the flagellar biosynthesis cascade (Subashchandrabose and Mobley, 2015), and the highly antigenic flagellin, encoded by fliC

(Acharya et al., 2019), were not differentially expressed in *E. coli* 83972 *attB::lsr* (Table 2, Supplementary Table S1), and since *E. coli* 83972 expresses only little flagella (Hancock et al., 2008), it appears unlikely that the further downregulation of already weakly expressed flagellar genes is negatively impacting this strain's bladder colonization ability.

One of the main characteristics of E. coli 83972 is its fast growth in urine and, thus, the outgrowth of competing UPEC strains in direct competition (Roos et al., 2006; Ipe et al., 2016). One factor that might contribute to this higher competitiveness is metabolic adaptation (Ipe et al., 2016). We found several genes associated with metabolism to be differentially expressed in all three growth phases in E. coli 83972 attB::lsr (Table 1). AI-2-dependent QS was already linked to sugar metabolism (Ha et al., 2018), catabolite repression (Wang et al., 2005) and carbon regulation (Mitra et al., 2016). The strong upregulation of genes involved in the valine, leucine, and isoleucine biosynthesis (ilv operon) was interesting since *ilvA* and *ilvC* were found to be essential factors during growth in urine (Vejborg et al., 2012), probably because the overall concentrations of the three amino acids are relatively low as compared to other amino acids in urine (Bouatra et al., 2013) (Table 1, Supplementary Table S1). In E. coli strain CFT073, valine overproduction is considered a metabolic adaptation during biofilm formation (Valle et al., 2008). We also found several genes related to biofilm formation and adhesion upregulated in the transition to the stationary phase upon restoration of the lsr operon (Supplementary Table S1, Table 2). Thus, we checked for biofilm formation according to the protocol of (Laganenka et al., 2016). in E. coli strains 83972 and 83972 attB::lsr, but observed no significant differences (Supplementary Figure S7). Thus, the observed lsrdependent upregulation of the *ilv* genes had no marked effect on biofilm formation of E. coli strain 83972 attB::lsr.

We wondered whether the differential regulation of metabolic genes in E. coli 83972 attB::lsr might affect growth. Indeed, we observed a growth retardation of this strain compared to the lsrnegative wild type 83972, independent of growth medium or oxygen availability (Figure 4, Supplementary Figure S3). Consistent with the findings of Sperandio and colleagues made in EHEC strain 86-24 (Sperandio et al., 2001), we observed that the deletion of luxS resulted in a significantly longer lag phase of E. coli strain 83972 (Supplementary Figure S8). Interestingly, the restoration of the lsr determinant in E. coli 83972 significantly extended the lag phase as well as the doubling time of E. coli 83972 (Supplementary Figure S8). As we did not observe an additive effect of luxS deletion and lsr restoration on the length of the lag phase in E. coli 83972, and since luxS was not differentially expressed in E. coli 83972 attB::lsr in all three growth phases, the longer lag phase of the strains 83972 $\Delta luxS$ and 83972 *AluxS attB::lsr* as compared to the wild type might thus be due to the loss of LuxS as metabolic enzyme (Schauder et al., 2001; Vendeville et al., 2005; Zdziarski et al., 2008) and not due to AI-2 secretion, as E. coli 83972 and E. coli 83972 AluxS are not able to sense AI-2. Taken together, these findings showed that the presence of the full-length lsr locus alone was not sufficient to cause the observed slowdown in growth but that it most likely resulted from an AI-2-dependent deregulation of specific gene expression. Because we performed the complementation as a single copy-insertion of the *lsr* determinant into a neutral site of the chromosome, overexpression effects and artificial phenotypes due to incompatibilities in gene regulation or metabolic stress caused by overexpression should be excluded. To validate our assumption, additional *E. coli* isolates will have to be tested for their *lsr*-dependent growth characteristics. In this context, fitness costs from the two *cat* and *aph* resistance cassettes used for complementation could be considered as well as non-QS-related functions of the *lsr* determinant.

In the intestinal tract, where the bacterial composition is diverse and the bacterial load is high, a negative effect of AI-2-dependent QS on growth rate does not necessarily lead to a reduction in fitness as AI-2-dependent QS significantly impacts microbiota composition, which in turn affects the fitness of individual bacterial species (Christiaen et al., 2014; Thompson et al., 2015; Deng et al., 2022). Nevertheless, our feeding experiments of G. mellonella larvae with equal ratios of E. coli 83972 wild type and the lsr-complemented strain impressively showed that the restoration of the lsr operon significantly reduced the colonization ability and competitiveness of E. coli 83972 attB::lsr in the digestive tract compared to the lsr-negative parent strain. We are fully aware that the human intestinal tract and that of G. mellonella larvae differ substantially, not only in their microbiome composition. We applied G. mellonella larvae as a 3R-compliant model to investigate the ability of E. coli 83972 to assert itself in a niche densely populated by a complex microbiota. We view this experiment as a proxy for intestinal colonization and understand that a more relevant colonization model for the human digestive tract must be used in further studies to clarify the impact of AI-2dependent QS on the intestinal colonization capacity of phylogroup B2 strains. It has recently been described in a mouse model that AI-2 production increases chemotaxis and thus the metabolic traitdependent fitness of E. coli strain Z1331 in the intestine. AI-2dependent chemotaxis can also promote the coexistence of different E. coli strains in the intestine through niche segregation (Laganenka et al., 2023). Related to hardly flagellated E. coli strain 83972, we interpret our results as indicating that the importance of AI-2 in bacterial fitness in the digestive tract can be strain-dependent and influenced by individual metabolic and phenotypic characteristics. In the human bladder, however, where bacterial numbers are typically not as high as in the intestinal tract (Perez-Carrasco et al., 2021), regulating growth by monitoring cell density may be a disadvantage for urine isolates, because of rapid changes of the population size in the bladder. The urine void drastically reduces the overall bacterial count and volume of the growth compartment, urging non-voided bacteria to regrow fast to maintain bladder colonization, especially when competing with a second bacterial species (Ipe et al., 2016). QS is known to slow down growth and metabolism as soon as a high cell density is reached (Sperandio et al., 2001; An et al., 2014). When the bacteria encounter a rapid reduction in cell density, this switch leads to a subsequent adaptation of gene expression in quorum sensing strains (Pereira et al., 2013), which likely differs from that in bacteria that cannot sense the bacterial cell density. In our co-cultivation experiment,

where the lsr-positive strain 83972 attB::lsr (pLS1) and the lsrnegative strain 83972 (pLS2) were in direct competition, the lsrpositive variant capable of QS was outcompeted by the isogenic lsrnegative wild type, which is unable to sense bacterial cell density but displays a shorter lag phase and doubling time (Figure 4). The observed slowdown in growth and prolonged doubling time of the lsr-positive variant could underlie the displacement of this mutant by the QS-insensitive wild type due to QS-dependent adaptations in gene expression. Especially in the case of frequent changes in population density, here mimicked by serial passage after 3 h of growth (Figure 5A), compared to the long-term competition experiment (Figure 5B), the displacement by the lsr-negative strain is particularly evident. This property benefits E. coli 83972 in bacterial interference in the urinary bladder because it can compensate for bottlenecks due to rapid reductions in population size as a result of repeated voiding. In summary, our results suggest that the differential expression of metabolic genes by AI-2dependent QS may result in different growth characteristics and reduced competitiveness of E. coli 83972 attB::lsr. The direct evidence, however, is still missing, and the precise regulatory mechanisms remain to be elucidated.

The nrdHIEF operon was upregulated during mUTI/hUTI as compared to growth in LB (Frick-Cheng et al., 2020), and we found nrdHIEF upregulated in E. coli 83972 attB::lsr as compared to E. coli 83972 in the lag phase (Table 3). Though the operon encodes a ribonucleotide reductase that is required for dNTP synthesis and is thus associated with DNA synthesis, nrdHIEF expression was found to be stimulated upon oxidative stress, particularly in mutants that miss major antioxidant defenses (Monje-Casas et al., 2001). It is thought that E. coli overexpresses several reductases and electron donors, including nrdHIEF, to cope with oxidative stress (Monje-Casas et al., 2001; Abdelwahed et al., 2022). Interestingly, the gene ybhC, which leads to a significantly lower minimal inhibitory concentration against H₂O₂ when deleted in the E. coli strain BW25113 (Chen et al., 2021), was the most strongly downregulated gene during the lag and exponential growth phase and was also strongly downregulated during the transition to the stationary phase in *E. coli* 83972 attB::lsr (Supplementary Table S1). We wondered whether this strong downregulation might contribute to a higher sensitivity to H2O2. Therefore, we challenged E. coli 83972, its isogenic ybhC deletion mutant 83972 Δ ybhC, and E. coli 83972 attB::lsr with H₂O₂ concentrations that can be physiologically measured in human urine (Varma and Devamanoharan, 1990). Indeed, we observed that E. coli 83972 was more resistant to H₂O₂ than the strains 83972 $\Delta ybhC$ and 83972 *attB*::*lsr* (Figure 6). We observed that the *ybhC* deletion did not affect the length of the lag phase as compared to E. coli 83972 (unpaired t-test; p = 0.19), whereas E. coli 83972 attB::lsr had a significantly longer lag phase than both, E. coli 83972 and E. coli 83972 ΔybhC (Figure 6). Thus, the overall longer lag phase of the lsr-positive variant of strain 83972 does not explain its higher sensitivity to H2O2, while the strong downregulation of ybhC in this strain might be one factor responsible for this phenotype. Notably, the increased H₂O₂ sensitivity of E. coli 83972 attB::lsr is in agreement with a previous report of increased H2O2 sensitivity in the MPEC strain DCM5 expressing a functional LsrR (Wang et al., 2021). However, in this MPEC strain, the higher sensitivity was explained by LsrRmediated repression of H2O2 scavenging enzyme-encoding genes, including ahpCF. As opposed to that, we found that ahpCF was slightly upregulated in strain 83972 attB::lsr in the lag phase (Supplementary Table S1). Therefore, the decreased expression of ahpCF is unlikely to explain the lsr-dependent sensitivity of E. coli 83972 to H2O2. E. coli 83972 has an increased level of endogenous reactive oxygen species while growing in urine compared to other ABU and UPEC strains, but correspondingly, it also has a more active antioxidant defense system (Aubron et al., 2012). We found several differentially expressed genes in E. coli 83972 attB::lsr that have been associated with oxidative stress in other studies (Supplementary Table S4) or other stress-related responses (Table 4). Thus, the overall H₂O₂ detoxification or stress response seems to be imbalanced in the presence of functional AI-2dependent QS in E. coli 83972 attB::lsr, resulting in a higher sensitivity against oxidative stress. During ABU, however, increased sensitivity to H2O2 is a disadvantage since the infiltration of activated neutrophils into the bladder represents one host defense mechanism to kill bacteria with reactive oxygen species during UTI (Demirel et al., 2020). Especially in a competition situation in the bladder, a significantly prolonged lag phase and doubling time of E. coli 83972 attB::lsr in addition to the increased H₂O₂ sensitivity could constitute a clear colonization disadvantage relative to the lsr-negative wild type strain (Supplementary Figure S5).

AI-2-dependent QS in ExPEC has pleiotropic effects since it contributes to virulence, colonization, and antibiotic resistance but also H₂O₂ sensitivity, metabolism, and growth defects, as can also be seen in our study (Xue et al., 2009; Kathayat et al., 2021; Wang et al., 2021). Epidemiological studies have shown that ExPEC frequently belong to the phylogroup B2 (Picard et al., 1999; Micenková et al., 2016). However, in the collection of E. coli genomes we examined, genomes of phylogroup A and B1 isolates were predominant (Supplementary Table S2). Intriguingly, it was already suggested that E. coli strains of the phylogroup B2 might have lost the lsr locus during evolution (Quan and Bentley, 2012; Brito et al., 2013). However, all B2 strains analyzed by Brito and colleagues encoded a functional LuxS synthase and thus should be capable of producing AI-2 (Brito et al., 2013). Following Brito and colleagues, we found that the vast majority of E. coli belonging to the phylogroup B2 lack a full-length lsr locus (Figure 8, Supplementary Figure S6A), while the presence of luxS seems to be remarkably conserved (Supplementary Figure S6B). The high prevalence of luxS in E. coli and also over a long time in bacteria (Santiago-Rodriguez et al., 2014) underlines its crucial role as a metabolic enzyme in the activated methyl cycle (Vendeville et al., 2005). The tam gene, which is located downstream of the lsrACDBFG operon, was also widely distributed (> 88%) in the different phylogroups (Supplementary Figure S6C). Since E. coli 83972 encodes Tam and its role in AI-2-dependent QS remains unclear, we omitted tam from the complemented lsr locus. Indeed, we observed that tam was upregulated during the transition to the stationary phase (data not shown) but was not differentially

10.3389/fcimb.2025.1603759

expressed in E. coli 83972 attB::lsr as compared to E. coli 83972. Evolutionary studies suggest that the lsr locus was passed on via horizontal gene transfer (Rezzonico et al., 2012), and lateral gene transfer events were also described (Pereira et al., 2009). Thus, it is interesting that the operon was not reintroduced into the phylogroup B2 (Manges and Johnson, 2015). These observations and our data suggest that the loss of AI-2-dependent QS could be an evolutionary advantage for E. coli 83972, which efficiently colonizes the urinary bladder as an extraintestinal body niche. Whether the absence of the lsr determinant in almost all phylogroup B2 isolates investigated so far may be correlated, at least in part, with generally increased fitness properties in extraintestinal niches or superior colonization properties in densely populated niches such as the intestinal tract will require more detailed future analyses of the effect of *lsr* complementation in a diverse collection of phylogroup B2 strains.

5 Conclusion

It is imperative that we explore non-antibiotic solutions to prevent UTI, with bacterial interference being a promising avenue for treating symptomatic episodes of uncomplicated cystitis. Our study provides new information on gene regulation in E. coli 83972. The more we understand which bacterial characteristics improve fitness and colonization properties in the urinary bladder, the better we could rationally improve the engineering of E. coli 83972 or predict outcomes in therapeutic colonization. The impact of AI-2mediated QS for pathogenicity or fitness of ExPEC is not uniform and is probably dependent on the individual strain background. Whereas interference with AI-2-dependent QS resulted in downregulation of ExPEC virulence traits and attenuation in some isolates, increased fitness due to enhanced resistance to oxidative stress was observed in others. It is tempting to speculate that the absence of the *lsr* operon in the majority of phylogroup B2 isolates may potentially suggest that the loss of AI-2-dependent QS could be associated with a fitness advantage in extraintestinal niches or their reservoir, i.e., the intestinal tract. However, this must be further analyzed in detail in the future. In this study, we investigated the impact of AI-2-mediated QS on fitness traits of asymptomatic bacteriuria E. coli isolate 83972, a strain that has already been used for therapeutic bladder colonization, thereby interfering with bladder infections caused by uropathogens. We found that the reintroduction of AI-2-dependent QS in E. coli 83972, which is optimally adapted to the growth conditions in the urinary bladder, has led to a phenotype that is disadvantageous for efficient and longterm bladder colonization, especially in a competitive situation. Restoration of the lsr determinant in E. coli 83972 resulted in growth retardation, loss of competitiveness and increased susceptibility to oxidative stress, all characteristics relevant to this strain's colonization ability in the bladder. Thus, our findings indicate that the absence of AI-2-dependent QS in E. coli 83972 may be an advantage during the colonization of the urinary bladder. Further studies on the benefits of the lack of the lsr determinant in a broad spectrum of ExPEC isolates with different phylogenetic backgrounds and genome content are needed to gain deeper insights into the general importance of AI-2-dependent QS for *E. coli* fitness and pathogenicity in extraintestinal niches and or the colonization of the intestinal tract.

Data availability statement

The datasets presented in this study are publicly accessible at NCBI GEO (SRA accession number GSE300954). This data can be found here: (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE300954).

Ethics statement

Ethical approval was not required for the studies on humans in accordance with the local legislation and institutional requirements because only commercially available established cell lines were used. The manuscript presents research on animals that do not require ethical approval for their study.

Author contributions

MK: Data curation, Investigation, Methodology, Visualization, Writing – original draft, Writing – review & editing. KM: Data curation, Investigation, Methodology, Writing – review & editing. MB: Conceptualization, Formal analysis, Supervision, Validation, Writing – review & editing. UD: Conceptualization, Formal analysis, Funding acquisition, Resources, Supervision, Writing – review & editing.

Funding

The author(s) declare that financial support was received for the research and/or publication of this article. German Research Foundation grant no. 281125614/GRK2220 (EvoPAD project A3) German Research Foundation grant no. CRC1009/3, project B05.

Acknowledgments

Data reported in this study appear in part in the PhD thesis of M. Keizers. The authors thank H. Wami (Münster) and P. Berger (Münster) for helpful discussions and O. Mantel (Münster) for excellent technical support.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Generative AI statement

The author(s) declare that no Generative AI was used in the creation of this manuscript.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations,

References

Abdelwahed, E. K., Hussein, N. A., Moustafa, A., Moneib, N. A., and Aziz, R. K. (2022). Gene networks and pathways involved in *Escherichia coli* response to multiple stressors. *Microorganisms* 10. doi: 10.3390/microorganisms10091793

Abraham, S. N., and Miao, Y. (2015). The nature of immune responses to urinary tract infections. *Nat. Rev. Immunol.* 15, 655–663. doi: 10.1038/nri3887

Acharya, D., Sullivan, M. J., Duell, B. L., Goh, K. G. K., Katupitiya, L., Gosling, D., et al. (2019). Rapid bladder interleukin-10 synthesis in response to uropathogenic *Escherichia coli* is part of a defense strategy triggered by the major bacterial flagellar filament *fliC* and contingent on TLR5. *mSphere* 4, e00545–e00519. doi: 10.1128/mSphere.00545-19

An, J. H., Goo, E., Kim, H., Seo, Y. S., and Hwang, I. (2014). Bacterial quorum sensing and metabolic slowing in a cooperative population. *Proc. Natl. Acad. Sci. U.S.A.* 111, 14912–14917. doi: 10.1073/pnas.1412431111

Ascenso, O. S., Marques, J. C., Santos, A. R., Xavier, K. B., Ventura, M. R., and Maycock, C. D. (2011). An efficient synthesis of the precursor of AI-2, the signalling molecule for inter-species quorum sensing. *Bioorg Med. Chem.* 19, 1236–1241. doi: 10.1016/j.bmc.2010.12.036

Aubron, C., Glodt, J., Matar, C., Huet, O., Borderie, D., Dobrindt, U., et al. (2012). Variation in endogenous oxidative stress in *Escherichia coli* natural isolates during growth in urine. *BMC Microbiol* 12, 120. doi: 10.1186/1471-2180-12-120

Babraham Bioinformatics FastQC A Quality Control tool for High Throughput Sequence Data. Available online at: https://www.bioinformatics.babraham.ac.uk/ projects/fastqc/ (Accessed May 21, 2025).

Beghain, J., Bridier-Nahmias, A., Le Nagard, H., Denamur, E., and Clermont, O. (2018). ClermonTyping: an easy-to-use and accurate in silico method for *Escherichia* genus strain phylotyping. *Microb Genom* 4. doi: 10.1099/mgen.0.000192

Berger, M., Gerganova, V., Berger, P., Rapiteanu, R., Lisicovas, V., and Dobrindt, U. (2016). Genes on a wire: the nucleoid-associated protein HU insulates transcription units in *Escherichia coli*. *Sci. Rep.* 6, 31512. doi: 10.1038/srep31512

Bouatra, S., Aziat, F., Mandal, R., Guo, A. C., Wilson, M. R., Knox, C., et al. (2013). The human urine metabolome. *PloS One* 8, e73076. doi: 10.1371/journal.pone.0073076

Brito, P. H., Rocha, E. P., Xavier, K. B., and Gordo, I. (2013). Natural genome diversity of AI-2 quorum sensing in *Escherichia coli*: conserved signal production but labile signal reception. *Genome Biol. Evol.* 5, 16–30. doi: 10.1093/gbe/evs122

Camacho, C., Coulouris, G., Avagyan, V., Ma, N., Papadopoulos, J., Bealer, K., et al. (2009). BLAST+: architecture and applications. *BMC Bioinf.* 10, 421. doi: 10.1186/1471-2105-10-421

Chen, H. (2022). VennDiagram: Generate High-Resolution Venn and Euler Plots. Available online at: https://cloud.r-project.org/web/packages/VennDiagram/index. html (Accessed May 21, 2025).

Chen, H., Wilson, J., Ercanbrack, C., Smith, H., Gan, Q., and Fan, C. (2021). Genome-wide screening of oxidizing agent resistance genes in *Escherichia coli*. *Antioxidants* 10, 861. doi: 10.3390/antiox10060861

Chen, X., Schauder, S., Potier, N., Van Dorsselaer, A., Pelczer, I., Bassler, B. L., et al. (2002). Structural identification of a bacterial quorum-sensing signal containing boron. *Nature* 415, 545–549. doi: 10.1038/415545a

Choi, J., Shin, D., Kim, M., Park, J., Lim, S., and Ryu, S. (2012). LsrR-mediated quorum sensing controls invasiveness of *Salmonella typhimurium* by regulating SPI-1 and flagella genes. *PloS One* 7, e37059. doi: 10.1371/journal.pone.0037059

Christiaen, S. E., O'connell Motherway, M., Bottacini, F., Lanigan, N., Casey, P. G., Huys, G., et al. (2014). Autoinducer-2 plays a crucial role in gut colonization and probiotic functionality of *Bifidobacterium breve* UCC2003. *PloS One* 9, e98111. doi: 10.1371/journal.pone.0098111

Cook, M. A., and Wright, G. D. (2022). The past, present, and future of antibiotics. *Sci. Transl. Med.* 14, eabo7793. doi: 10.1126/scitranslmed.abo7793 or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fcimb.2025.1603759/ full#supplementary-material

Dainat, J. (2022). "Another Gtf/Gff Analysis Toolkit (AGAT): Resolve interoperability issues and accomplish more with your annotations. Available at: https://nbisweden.github.io/AGAT/ (Accessed May 21, 2025).

Datsenko, K. A., and Wanner, B. L. (2000). One-step inactivation of chromosomal genes in *Escherichia coli* K-12 using PCR products. *Proc. Natl. Acad. Sci. U.S.A.* 97, 6640–6645. doi: 10.1073/pnas.120163297

Demirel, I., Persson, A., Brauner, A., Sarndahl, E., Kruse, R., and Persson, K. (2020). Activation of NLRP3 by uropathogenic *Escherichia coli* is associated with IL-1beta release and regulation of antimicrobial properties in human neutrophils. *Sci. Rep.* 10, 21837. doi: 10.1038/s41598-020-78651-1

Deng, Z., Hou, K., Valencak, T. G., Luo, X. M., Liu, J., and Wang, H. (2022). AI-2/ LuxS Quorum Sensing System Promotes Biofilm Formation of *Lactobacillus rhamnosus* GG and Enhances the Resistance to Enterotoxigenic *Escherichia coli* in Germ-Free Zebrafish. *Microbiol Spectr.* 10, e0061022. doi: 10.1128/spectrum.00610-22

Ewels, P., Magnusson, M., Lundin, S., and Kaller, M. (2016). MultiQC: summarize analysis results for multiple tools and samples in a single report. *Bioinformatics* 32, 3047–3048. doi: 10.1093/bioinformatics/btw354

Farrell, K., Tandan, M., Hernandez Santiago, V., Gagyor, I., Braend, A. M., Skow, M., et al. (2021). Treatment of uncomplicated UTI in males: a systematic review of the literature. *BJGP Open* 5, bjgpopen20X101140. doi: 10.3399/bjgpopen20X101140

Flores-Mireles, A. L., Walker, J. N., Caparon, M., and Hultgren, S. J. (2015). Urinary tract infections: epidemiology, mechanisms of infection and treatment options. *Nat. Rev. Microbiol* 13, 269–284. doi: 10.1038/nrmicro3432

Frick-Cheng, A. E., Sintsova, A., Smith, S. N., Krauthammer, M., Eaton, K. A., and Mobley, H. L. T. (2020). The gene expression profile of uropathogenic *Escherichia coli* in women with uncomplicated urinary tract infections is recapitulated in the mouse model. *mBio* 11, e01412–e01420. doi: 10.1128/mBio.01412-20

George, I., Kalairaj, M. S., Zimmern, P. E., Ware, T. H., and Subashchandrabose, S. (2024). Competitive fitness of asymptomatic bacteriuria *E. coli* strain 83972 against uropathogens in human urine. *Infect. Immun.* 92, e0017324. doi: 10.1128/iai.00173-24

Ha, J. H., Hauk, P., Cho, K., Eo, Y., Ma, X., Stephens, K., et al. (2018). Evidence of link between quorum sensing and sugar metabolism in *Escherichia coli* revealed via cocrystal structures of LsrK and HPr. *Sci. Adv.* 4, eaar7063. doi: 10.1126/sciadv.aar7063

Han, X., Bai, H., Tu, J., Yang, L., Xu, D., Wang, S., et al. (2015). Deletion of *luxS* further attenuates the virulence of the avian pathogenic *Escherichia coli aroA* mutant. *Microb Pathog* 88, 39–47. doi: 10.1016/j.micpath.2015.08.003

Hancock, V., Seshasayee, A. S., Ussery, D. W., Luscombe, N. M., and Klemm, P. (2008). Transcriptomics and adaptive genomics of the asymptomatic bacteriuria *Escherichia coli* strain 83972. *Mol. Genet. Genomics* 279, 523–534. doi: 10.1007/s00438-008-0330-9

Helmy, Y. A., Kathayat, D., Deblais, L., Srivastava, V., Closs, G.Jr., Tokarski, R. J. 2nd, et al. (2022). Evaluation of novel quorum sensing inhibitors targeting auto-inducer 2 (AI-2) for the control of avian pathogenic *Escherichia coli* infections in chickens. *Microbiol Spectr.* 10, e0028622. doi: 10.1128/spectrum.00286-22

Henly, E. L., Norris, K., Rawson, K., Zoulias, N., Jaques, L., Chirila, P. G., et al. (2021). Impact of long-term quorum sensing inhibition on uropathogenic *Escherichia coli. J. Antimicrob Chemother.* 76, 909–919. doi: 10.1093/jac/dkaa517

Hull, R. A., Rudy, D. C., Donovan, W. H., Wieser, I. E., Stewart, C., and Darouiche, R. O. (1999). Virulence properties of *Escherichia coli* 83972, a prototype strain associated with asymptomatic bacteriuria. *Infect. Immun.* 67, 429–432. doi: 10.1128/IAI.67.1.429-432.1999

Ipe, D. S., Horton, E., and Ulett, G. C. (2016). The basics of bacteriuria: strategies of microbes for persistence in urine. *Front. Cell Infect. Microbiol* 6, 14. doi: 10.3389/ fcimb.2016.00014

Ismail, A. S., Valastyan, J. S., and Bassler, B. L. (2016). A host-produced autoinducer-2 mimic activates bacterial quorum sensing. *Cell Host Microbe* 19, 470–480. doi: 10.1016/j.chom.2016.02.020

Kathayat, D., Lokesh, D., Ranjit, S., and Rajashekara, G. (2021). Avian pathogenic *Escherichia coli* (APEC): an overview of virulence and pathogenesis factors, zoonotic potential, and control strategies. *Pathogens* 10, 467. doi: 10.3390/pathogens10040467

Keizers, M., Dobrindt, U., and Berger, M. (2022). A simple biosensor-based assay for quantitative autoinducer-2 analysis. ACS Synth Biol. 11, 747–759. doi: 10.1021/acssynbio.1c00459

Kenneally, C., Murphy, C. P., Sleator, R. D., and Culligan, E. P. (2022). The urinary microbiome and biological therapeutics: Novel therapies for urinary tract infections. *Microbiol Res.* 259, 127010. doi: 10.1016/j.micres.2022.127010

Khera, R., Mehdipour, A. R., Bolla, J. R., Kahnt, J., Welsch, S., Ermler, U., et al. (2022). Cryo-EM structures of pentameric autoinducer-2 exporter from *Escherichia coli* reveal its transport mechanism. *EMBO J.* 41, e109990. doi: 10.15252/embj.2021109990

Kitts, P. A., Church, D. M., Thibaud-Nissen, F., Choi, J., Hem, V., Sapojnikov, V., et al. (2016). Assembly: a resource for assembled genomes at NCBI. *Nucleic Acids Res.* 44, D73–D80. doi: 10.1093/nar/gkv1226

Köhler, C. D., and Dobrindt, U. (2011). What defines extraintestinal pathogenic Escherichia coli? Int. J. Med. Microbiol 301, 642-647. doi: 10.1016/j.ijmm.2011.09.006

Kolde, R. (2019). Package 'pheatmap'. Available online at: https://cran.r-project.org/ web//packages/pheatmap/pheatmap.pdf (Accessed May 21, 2025).

Köves, B., Salvador, E., Gronberg-Hernandez, J., Zdziarski, J., Wullt, B., Svanborg, C., et al. (2014). Rare emergence of symptoms during long-term asymptomatic *Escherichia coli* 83972 carriage without an altered virulence factor repertoire. *J. Urol* 191, 519–528. doi: 10.1016/j.juro.2013.07.060

Laganenka, L., Colin, R., and Sourjik, V. (2016). Chemotaxis towards autoinducer 2 mediates autoaggregation in *Escherichia coli*. *Nat. Commun.* 7, 12984. doi: 10.1038/ ncomms12984

Laganenka, L., Lee, J. W., Malfertheiner, L., Dieterich, C. L., Fuchs, L., Piel, J., et al. (2023). Chemotaxis and autoinducer-2 signalling mediate colonization and contribute to co-existence of *Escherichia coli* strains in the murine gut. *Nat. Microbiol* 8, 204–217. doi: 10.1038/s41564-022-01286-7

Laganenka, L., and Sourjik, V. (2018). Autoinducer 2-dependent *Escherichia coli* biofilm formation is enhanced in a dual-species coculture. *Appl. Environ. Microbiol* 84, e02638–e02617. doi: 10.1128/AEM.02638-17

Lane, M. C., Lockatell, V., Monterosso, G., Lamphier, D., Weinert, J., Hebel, J. R., et al. (2005). Role of motility in the colonization of uropathogenic *Escherichia coli* in the urinary tract. *Infect. Immun.* 73, 7644–7656. doi: 10.1128/IAI.73.11.7644-7656.2005

Lange, A., Schäfer, A., and Frick, J. S. (2019). A *Galleria mellonella* oral administration model to study commensal-induced innate immune responses. *J. Vis Exp.* 145, e59270. doi: 10.3791/59270

Li, J., Attila, C., Wang, L., Wood, T. K., Valdes, J. J., and Bentley, W. E. (2007). Quorum sensing in *Escherichia coli* is signaled by AI-2/LsrR: effects on small RNA and biofilm architecture. *J. Bacteriol* 189, 6011–6020. doi: 10.1128/JB.00014-07

Li, H., and Durbin, R. (2009). Fast and accurate short read alignment with Burrows-Wheeler transform. *Bioinformatics* 25, 1754–1760. doi: 10.1093/bioinformatics/btp324

Liao, Y., Smyth, G. K., and Shi, W. (2014). featureCounts: an efficient general purpose program for assigning sequence reads to genomic features. *Bioinformatics* 30, 923–930. doi: 10.1093/bioinformatics/btt656

Lila, A. S. A., Rajab, A. A. H., Abdallah, M. H., Rizvi, S. M. D., Moin, A., Khafagy, E. S., et al. (2023). Biofilm lifestyle in recurrent urinary tract infections. *Life* 13, 148. doi: 10.3390/life13010148

Loubet, P., Ranfaing, J., Dinh, A., Dunyach-Remy, C., Bernard, L., Bruyere, F., et al. (2020). Alternative therapeutic options to antibiotics for the treatment of urinary tract infections. *Front. Microbiol* 11, 1509. doi: 10.3389/fmicb.2020.01509

Love, M. I., Huber, W., and Anders, S. (2014). Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. *Genome Biol.* 15, 550. doi: 10.1186/ s13059-014-0550-8

Manges, A. R., and Johnson, J. R. (2015). Reservoirs of extraintestinal pathogenic Escherichia coli. Microbiol Spectr. 3. doi: 10.1128/microbiolspec.uti-0006-2012

Mann, R., Mediati, D. G., Duggin, I. G., Harry, E. J., and Bottomley, A. L. (2017). Metabolic adaptations of uropathogenic *E. coli* in the urinary tract. *Front. Cell Infect. Microbiol* 7, 241. doi: 10.3389/fcimb.2017.00241

Marques, J. C., Lamosa, P., Russell, C., Ventura, R., Maycock, C., Semmelhack, M. F., et al. (2011). Processing the interspecies quorum-sensing signal autoinducer-2 (AI-2): characterization of phospho-(S)-4,5-dihydroxy-2,3-pentanedione isomerization by LsrG protein. J. Biol. Chem. 286, 18331–18343. doi: 10.1074/jbc.M111.230227

Marques, J. C., Oh, I. K., Ly, D. C., Lamosa, P., Ventura, M. R., Miller, S. T., et al. (2014). LsrF, a coenzyme A-dependent thiolase, catalyzes the terminal step in processing the quorum sensing signal autoinducer-2. *Proc. Natl. Acad. Sci. U.S.A.* 111, 14235–14240. doi: 10.1073/pnas.1408691111

Martin, M. (2011). CUTADAPT removes adapter sequences from high-throughput sequencing reads. *EMBnet J.* 17, 10–12. doi: 10.14806/ej.17.1.200

Medina, M., and Castillo-Pino, E. (2019). An introduction to the epidemiology and burden of urinary tract infections. *Ther. Adv. Urol* 11, 1756287219832172. doi: 10.1177/1756287219832172

Micenková, L., Bosák, J., Vrba, M., Ševčíková, A., and Šmajs, D. (2016). Human extraintestinal pathogenic *Escherichia coli* strains differ in prevalence of virulence factors, phylogroups, and bacteriocin determinants. *BMC Microbiol* 16, 218. doi: 10.1186/s12866-016-0835-z

Midani, F. S., Collins, J., and Britton, R. A. (2021). AMiGA: software for automated analysis of microbial growth assays. *mSystems* 6, e0050821. doi: 10.1128/msystems.00508-21

Miller, S. T., Xavier, K. B., Campagna, S. R., Taga, M. E., Semmelhack, M. F., Bassler, B. L., et al. (2004). *Salmonella typhimurium* recognizes a chemically distinct form of the bacterial quorum-sensing signal AI-2. *Mol. Cell* 15, 677–687. doi: 10.1016/j.molcel.2004.07.020

Mitra, A., Herren, C. D., Patel, I. R., Coleman, A., and Mukhopadhyay, S. (2016). Integration of AI-2 based cell-cell signaling with metabolic cues in *Escherichia coli*. *PloS One* 11, e0157532. doi: 10.1371/journal.pone.0157532

Monje-Casas, F., Jurado, J., Prieto-Alamo, M. J., Holmgren, A., and Pueyo, C. (2001). Expression analysis of the *nrdHIEF* operon from *Escherichia coli*. Conditions that trigger the transcript level in *vivo*. J. Biol. Chem. 276, 18031–18037. doi: 10.1074/ jbc.M011728200

Mukherjee, K., Amsel, D., Kalsy, M., Billion, A., Dobrindt, U., and Vilcinskas, A. (2020). MicroRNAs regulate innate immunity against uropathogenic and commensallike *Escherichia coli* infections in the surrogate insect model *Galleria mellonella*. *Sci. Rep.* 10, 2570. doi: 10.1038/s41598-020-59407-3

Nesta, B., Valeri, M., Spagnuolo, A., Rosini, R., Mora, M., Donato, P., et al. (2014). SslE elicits functional antibodies that impair *in vitro* mucinase activity and *in vivo* colonization by both intestinal and extraintestinal *Escherichia coli* strains. *PloS Pathog* 10, e1004124. doi: 10.1371/journal.ppat.1004124

Palaniyandi, S., Mitra, A., Herren, C. D., Zhu, X., and Mukhopadhyay, S. (2013). LuxS contributes to virulence in avian pathogenic *Escherichia coli* O78:K80:H9. *Vet Microbiol* 166, 567–575. doi: 10.1016/j.vetmic.2013.07.009

Peng, L., Dumevi, R. M., Chitto, M., Haarmann, N., Berger, P., Koudelka, G., et al. (2022). A robust one-step recombineering system for enterohemorrhagic *Escherichia coli. Microorganisms* 10, 1689. doi: 10.3390/microorganisms10091689

Pereira, C. S., De Regt, A. K., Brito, P. H., Miller, S. T., and Xavier, K. B. (2009). Identification of functional LsrB-like autoinducer-2 receptors. *J. Bacteriol* 191, 6975–6987. doi: 10.1128/JB.00976-09

Pereira, C. S., Santos, A. J., Bejerano-Sagie, M., Correia, P. B., Marques, J. C., and Xavier, K. B. (2012). Phosphoenolpyruvate phosphotransferase system regulates detection and processing of the quorum sensing signal autoinducer-2. *Mol. Microbiol* 84, 93–104. doi: 10.1111/j.1365-2958.2012.08010.x

Pereira, C. S., Thompson, J. A., and Xavier, K. B. (2013). AI-2-mediated signalling in bacteria. *FEMS Microbiol Rev.* 37, 156–181. doi: 10.1111/j.1574-6976.2012.00345.x

Perez-Carrasco, V., Soriano-Lerma, A., Soriano, M., Gutierrez-Fernandez, J., and Garcia-Salcedo, J. A. (2021). Urinary microbiome: yin and yang of the urinary tract. *Front. Cell Infect. Microbiol* 11, 617002. doi: 10.3389/fcimb.2021.617002

Picard, B., Garcia, J. S., Gouriou, S., Duriez, P., Brahimi, N., Bingen, E., et al. (1999). The link between phylogeny and virulence in *Escherichia coli* extraintestinal infection. *Infect. Immun.* 67, 546–553. doi: 10.1128/IAI.67.2.546-553.1999

Quan, D. N., and Bentley, W. E. (2012). Gene network homology in prokaryotes using a similarity search approach: queries of quorum sensing signal transduction. *PloS Comput. Biol.* 8, e1002637. doi: 10.1371/journal.pcbi.1002637

R: The R Project for Statistical Computing. Available online at: https://www.r-project.org/ (Accessed May 21, 2025).

Revelle, W. (2023). Package 'psych': Procedures for Psychological, Psychometric, and Personality Research. Available online at: https://cran.r-project.org/web/packages/ psych/psych.pdf (Accessed May 21, 2025).

Rezzonico, F., and Duffy, B. (2008). Lack of genomic evidence of AI-2 receptors suggests a non-quorum sensing role for *luxS* in most bacteria. *BMC Microbiol* 8, 154. doi: 10.1186/1471-2180-8-154

Rezzonico, F., Smits, T. H., and Duffy, B. (2012). Detection of AI-2 receptors in genomes of *Enterobacteriaceae* suggests a role of type-2 quorum sensing in closed ecosystems. *Sensors* 12, 6645–6665. doi: 10.3390/s120506645

Rodriguez-Siek, K. E., Giddings, C. W., Doetkott, C., Johnson, T. J., Fakhr, M. K., and Nolan, L. K. (2005). Comparison of *Escherichia coli* isolates implicated in human urinary tract infection and avian colibacillosis. *Microbiology* 151, 2097–2110. doi: 10.1099/mic.0.27499-0

Roos, V., Ulett, G. C., Schembri, M. A., and Klemm, P. (2006). The asymptomatic bacteriuria *Escherichia coli* strain 83972 outcompetes uropathogenic *E. coli* strains in human urine. *Infect. Immun.* 74, 615–624. doi: 10.1128/IAI.74.1.615-624.2006

Rutherford, S. T., and Bassler, B. L. (2012). Bacterial quorum sensing: its role in virulence and possibilities for its control. *Cold Spring Harb Perspect. Med.* 2, a012427. doi: 10.1101/cshperspect.a012427

Santiago-Rodriguez, T. M., Patricio, A. R., Rivera, J. I., Coradin, M., Gonzalez, A., Tirado, G., et al. (2014). *luxS* in bacteria isolated from 25- to 40-million-year-old amber. *FEMS Microbiol Lett.* 350, 117–124. doi: 10.1111/fml.2014.350.issue-1

Schauder, S., Shokat, K., Surette, M. G., and Bassler, B. L. (2001). The LuxS family of bacterial autoinducers: biosynthesis of a novel quorum-sensing signal molecule. *Mol. Microbiol* 41, 463–476. doi: 10.1046/j.1365-2958.2001.02532.x

Schiller, P., Knödler, M., Berger, P., Greune, L., Fruth, A., Mellmann, A., et al. (2021). The superior adherence phenotype of *E. coli* O104:H4 is directly mediated by the aggregative adherence fimbriae type I. *Virulence* 12, 346–359. doi: 10.1080/21505594.2020.1868841

Schneider, R., Lockatell, C. V., Johnson, D., and Belas, R. (2002). Detection and mutation of a *luxS*-encoded autoinducer in *Proteus mirabilis*. *Microbiology* 148, 773–782. doi: 10.1099/00221287-148-3-773

Sora, V. M., Meroni, G., Martino, P. A., Soggiu, A., Bonizzi, L., and Zecconi, A. (2021). Extraintestinal pathogenic *Escherichia coli*: virulence factors and antibiotic resistance. *Pathogens* 10, 1355. doi: 10.3390/pathogens10111355

Sperandio, V., Torres, A. G., Giron, J. A., and Kaper, J. B. (2001). Quorum sensing is a global regulatory mechanism in enterohemorrhagic *Escherichia coli* O157:H7. *J. Bacteriol* 183, 5187–5197. doi: 10.1128/JB.183.17.5187-5197.2001

Stork, C., Kovacs, B., Rozsai, B., Putze, J., Kiel, M., Dorn, A., et al. (2018). Characterization of Asymptomatic Bacteriuria *Escherichia coli* Isolates in Search of Alternative Strains for Efficient Bacterial Interference against Uropathogens. *Front. Microbiol* 9, 214. doi: 10.3389/fmicb.2018.00214

Subashchandrabose, S., and Mobley, H. L. T. (2015). Virulence and fitness determinants of uropathogenic *Escherichia coli*. *Microbiol Spectr.* 3. doi: 10.1128/microbiolspec.UTI-0015-2012

Sun, J., Daniel, R., Wagner-Döbler, I., and Zeng, A. P. (2004). Is autoinducer-2 a universal signal for interspecies communication: a comparative genomic and phylogenetic analysis of the synthesis and signal transduction pathways. *BMC Evol. Biol.* 4, 36. doi: 10.1186/1471-2148-4-36

Sundén, F., Håkansson, L., Ljunggren, E., and Wullt, B. (2010). *Escherichia coli* 83972 bacteriuria protects against recurrent lower urinary tract infections in patients with incomplete bladder emptying. *J. Urol* 184, 179–185. doi: 10.1016/j.juro.2010.03.024

Taga, M. E., Miller, S. T., and Bassler, B. L. (2003). Lsr-mediated transport and processing of AI-2 in *Salmonella typhimurium*. *Mol. Microbiol* 50, 1411–1427. doi: 10.1046/j.1365-2958.2003.03781.x

Taga, M. E., Semmelhack, J. L., and Bassler, B. L. (2001). The LuxS-dependent autoinducer AI-2 controls the expression of an ABC transporter that functions in AI-2 uptake in *Salmonella typhimurium. Mol. Microbiol* 42, 777–793. doi: 10.1046/j.1365-2958.2001.02669.x

Thompson, J. A., Oliveira, R. A., Djukovic, A., Ubeda, C., and Xavier, K. B. (2015). Manipulation of the quorum sensing signal AI-2 affects the antibiotic-treated gut microbiota. *Cell Rep.* 10, 1861–1871. doi: 10.1016/j.celrep.2015.02.049

Tivendale, K. A., Logue, C. M., Kariyawasam, S., Jordan, D., Hussein, A., Li, G., et al. (2010). Avian-pathogenic *Escherichia coli* strains are similar to neonatal meningitis *E. coli* strains and are able to cause meningitis in the rat model of human disease. *Infect. Immun.* 78, 3412–3419. doi: 10.1128/IAI.00347-10

Trappetti, C., Mcallister, L. J., Chen, A., Wang, H., Paton, A. W., Oggioni, M. R., et al. (2017). Autoinducer 2 Signaling via the Phosphotransferase FruA Drives Galactose Utilization by *Streptococcus pneumoniae*, Resulting in Hypervirulence. *mBio* 8, e02269– e02216. doi: 10.1128/mBio.02269-16

Valastyan, J. S., Kraml, C. M., Pelczer, I., Ferrante, T., and Bassler, B. L. (2021). *Saccharomyces cerevisiae* requires CFF1 to produce 4-hydroxy-5-methylfuran-3(2H)one, a mimic of the bacterial quorum-sensing autoinducer AI-2. *mBio* 12, e03303– e03320. doi: 10.1128/mBio.03303-20

Valle, J., Da Re, S., Schmid, S., Skurnik, D., D'ari, R., and Ghigo, J. M. (2008). The amino acid valine is secreted in continuous-flow bacterial biofilms. *J. Bacteriol* 190, 264–274. doi: 10.1128/JB.01405-07

Varma, S. D., and Devamanoharan, P. S. (1990). Excretion of hydrogen peroxide in human urine. *Free Radic. Res. Commun.* 8, 73–78. doi: 10.3109/10715769009087976

Vejborg, R. M., De Evgrafov, M. R., Phan, M. D., Totsika, M., Schembri, M. A., and Hancock, V. (2012). Identification of genes important for growth of asymptomatic

bacteriuria Escherichia coli in urine. Infect. Immun. 80, 3179–3188. doi: 10.1128/ IAI.00473-12

Vendeville, A., Winzer, K., Heurlier, K., Tang, C. M., and Hardie, K. R. (2005). Making 'sense' of metabolism: autoinducer-2, LuxS and pathogenic bacteria. *Nat. Rev. Microbiol* 3, 383–396. doi: 10.1038/nrmicro1146

Vila, J., Saez-Lopez, E., Johnson, J. R., Römling, U., Dobrindt, U., Canton, R., et al. (2016). *Escherichia coli*: an old friend with new tidings. *FEMS Microbiol Rev.* 40, 437–463. doi: 10.1093/femsre/fuw005

Wallenstein, A., Rehm, N., Brinkmann, M., Selle, M., Bossuet-Greif, N., Sauer, D., et al. (2020). ClbR is the key transcriptional activator of colibactin gene expression in *escherichia coli. mSphere* 5, e00591–e00520. doi: 10.1128/msphere.00591-20

Wang, L., Hashimoto, Y., Tsao, C. Y., Valdes, J. J., and Bentley, W. E. (2005). Cyclic AMP (cAMP) and cAMP receptor protein influence both synthesis and uptake of extracellular autoinducer 2 in *Escherichia coli*. *J. Bacteriol* 187, 2066–2076. doi: 10.1128/JB.187.6.2066-2076.2005

Wang, R. F., and Kushner, S. R. (1991). Construction of versatile low-copy-number vectors for cloning, sequencing and gene expression in *Escherichia coli*. *Gene* 100, 195–199. doi: 10.1016/0378-1119(91)90366-J

Wang, H., Shang, F., Shen, J., Xu, J., Chen, X., Ni, J., et al. (2021). LsrR, the effector of AI-2 quorum sensing, is vital for the H(2)O(2) stress response in mammary pathogenic *Escherichia coli. Vet Res.* 52, 127. doi: 10.1186/s13567-021-00998-8

Wang, L., Wang, S., and Li, W. (2012). RSeQC: quality control of RNA-seq experiments. *Bioinformatics* 28, 2184–2185. doi: 10.1093/bioinformatics/bts356

Wiles, T. J., Kulesus, R. R., and Mulvey, M. A. (2008). Origins and virulence mechanisms of uropathogenic *Escherichia coli. Exp. Mol. Pathol.* 85, 11–19. doi: 10.1016/j.yexmp.2008.03.007

Wullt, B., and Svanborg, C. (2016). Deliberate establishment of asymptomatic bacteriuria-A novel strategy to prevent recurrent UTI. *Pathogens* 5, 52. doi: 10.3390/pathogens5030052

Xavier, K. B., and Bassler, B. L. (2005). Regulation of uptake and processing of the quorum-sensing autoinducer AI-2 in *Escherichia coli. J. Bacteriol* 187, 238–248. doi: 10.1128/JB.187.1.238-248.2005

Xue, T., Yu, L., Shang, F., Li, W., Zhang, M., Ni, J., et al. (2016). Short communication: The role of autoinducer 2 (AI-2) on antibiotic resistance regulation in an *Escherichia coli* strain isolated from a dairy cow with mastitis. *J. Dairy Sci.* 99, 4693–4698. doi: 10.3168/jds.2015-10543

Xue, T., Zhao, L., Sun, H., Zhou, X., and Sun, B. (2009). LsrR-binding site recognition and regulatory characteristics in *Escherichia coli* AI-2 quorum sensing. *Cell Res.* 19, 1258–1268. doi: 10.1038/cr.2009.91

Yu, L., Li, W., Li, Q., Chen, X., Ni, J., Shang, F., et al. (2020). Role of LsrR in the regulation of antibiotic sensitivity in avian pathogenic *Escherichia coli*. *Poult Sci.* 99, 3675–3687. doi: 10.1016/j.psj.2020.03.064

Zargar, A., Quan, D. N., Carter, K. K., Guo, M., Sintim, H. O., Payne, G. F., et al. (2015). Bacterial secretions of nonpathogenic *Escherichia coli* elicit inflammatory pathways: a closer investigation of interkingdom signaling. *mBio* 6, e00025. doi: 10.1128/mBio.00025-15

Zdziarski, J., Svanborg, C., Wullt, B., Hacker, J., and Dobrindt, U. (2008). Molecular basis of commensalism in the urinary tract: low virulence or virulence attenuation? *Infect. Immun.* 76, 695–703. doi: 10.1128/IAI.01215-07

Zhang, L., Li, S., Liu, X., Wang, Z., Jiang, M., Wang, R., et al. (2020). Sensing of autoinducer-2 by functionally distinct receptors in prokaryotes. *Nat. Commun.* 11, 5371. doi: 10.1038/s41467-020-19243-5

Zuo, J., Yin, H., Hu, J., Miao, J., Chen, Z., Qi, K., et al. (2019). Lsr operon is associated with AI-2 transfer and pathogenicity in avian pathogenic *Escherichia coli*. *Vet Res.* 50, 109. doi: 10.1186/s13567-019-0725-0